4Front Ventures (FFNTF) 10-Q23 May 222022 Q1 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	3 Months Ended
Cover Page - shares	Mar. 31, 2022	May 30, 2022
Document Information [Line Items]
Entity Registrant Name	4Front Ventures Corp.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001783875
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-56075
Entity Incorporation, State or Country Code	A1
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		636,636,686
Entity Address, Address Line One	5060 N. 40th Street
Entity Address, Address Line Two	Suite 120
Entity Address, City or Town	Phoenix
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85018
City Area Code	602
Local Phone Number	633-3067
Entity Tax Identification Number	83-4168417
Class A Subordinate Voting Share [Member]
Document Information [Line Items]
Trading Symbol	FFNTF
Security Exchange Name	NONE
Title of 12(b) Security	Class A Subordinate Voting Shares, no par value
ADR [Member]
Document Information [Line Items]
Trading Symbol	FFNT
Security Exchange Name	NONE
Title of 12(b) Security	Class A Subordinate Voting Shares, no par value

CONDENSED CONSOLIDATED INTERIM

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash	$ 8,638	$ 22,581
Accounts receivable, net	2,742	1,946
Other receivables	1,802	289
Current portion of lease receivables	2,627	3,630
Inventory	25,910	20,087
Current portion of notes receivable	11	109
Prepaid expenses	2,079	2,232
Total current assets	43,809	50,874
Property, plant, and equipment, net	57,815	42,633
Lease receivables	7,543	6,748
Intangible assets, net	43,616	26,246
Goodwill	33,404	23,155
Right-of-use assets	99,395	100,519
Deposits	5,107	5,364
TOTAL ASSETS	290,689	255,539
Current liabilities:
Accounts payable	5,110	2,131
Accrued expenses and other current liabilities	7,596	9,411
Taxes payable	27,619	23,968
Derivative liability	2,202	3,502
Current portion of convertible notes	0	2,784
Current portion of lease liability	3,700	3,629
Current portion of notes payable and accrued interest	5,385	3,413
Total current liabilities	51,612	48,838
Convertible notes	14,920	14,641
Notes payable and accrued interest from related party	48,651	48,266
Long term notes payable	1,709	1,709
Long term accounts payable	1,200	1,200
Contingent consideration payable	2,393	2,393
Construction finance liability	16,000	0
Deferred tax liability	7,162	7,849
Lease liability	93,505	93,111
TOTAL LIABILITIES	237,152	218,007
SHAREHOLDERS' EQUITY
Equity attributable to 4Front Ventures Corp	294,981	274,120
Additional paid-in capital	53,235	52,197
Deficit	(294,756)	(288,857)
Non-controlling interest	77	72
TOTAL SHAREHOLDERS' EQUITY	53,537	37,532
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 290,689	$ 255,539

CONDENSED CONSOLIDATED INTERI_2

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
REVENUE
Revenue from sale of goods	$ 23,083	$ 20,080
Real estate income	2,965	2,890
Total revenues	26,048	22,970
Cost of goods sold	(12,594)	(9,125)
Gross profit	13,454	13,845
OPERATING EXPENSES
Selling and marketing expenses	5,166	5,157
General and administrative expenses	7,644	5,165
Depreciation and amortization	847	774
Equity based compensation	1,038	2,396
Total operating expenses	14,695	13,492
(Loss) Income from operations	(1,241)	353
Other income (expense)
Interest income	2	3
Interest expense	(2,620)	(2,461)
Amortization of loan discount upon conversion of debt to equity	0	(2,915)
Change in fair value of derivative liability	1,300	(2,532)
Loss on lease termination	0	(879)
Other	103	0
Total other expense, net	(1,215)	(8,784)
Net loss before income taxes	(2,456)	(8,431)
Income tax expense	(3,438)	(2,653)
Net loss from continuing operations	(5,894)	(11,084)
Net loss	(5,894)	(11,084)
Net income attributable to non-controlling interest	5	5
Net loss attributable to shareholders	$ (5,899)	$ (11,089)
Basic and diluted loss per share	$ (0.01)	$ (0.02)
Weighted average number of shares outstanding, basic and diluted	619,113,389	558,997,571

CONDENSED CONSOLIDATED INTERI_3

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Share Capital	Additional Paid-In Capital	Deficit	Total 4Front Ventures Corp. Shareholders' Equity	Non-Controlling Interest
Beginning Balance at Dec. 31, 2020	$ 42,203	$ 250,583	$ 42,116	$ (250,548)	$ 42,151	$ 52
Beginning Balance, Shares at Dec. 31, 2020	538,851,252	538,851,252
Shares issued for Pure Ratios earnout	$ 161	$ 161			161
Shares issued for Pure Ratios earnout, Shares		473,491
Share-based compensation	2,396		2,396		2,396
Conversion of notes to equity	6,253	$ 6,253			6,253
Conversion of notes to equity, shares		24,366,003
Shares issued with exercise of stock options	871	$ 871			871
Shares issued with exercise of stock options, shares		1,358,116
Shares issued with exercise of warrants	1,563	$ 1,563			1,563
Shares issued with exercise of warrants, shares		2,422,363
Return of treasury shares		(8,320)
Net loss	(11,084)			(11,089)	(11,089)	5
Ending Balance at Mar. 31, 2021	42,363	$ 259,431	44,512	(261,637)	42,306	57
Ending Balance, Shares at Mar. 31, 2021		567,462,905
Beginning Balance at Dec. 31, 2021	$ 37,532	$ 274,120	52,197	(288,857)	37,460	72
Beginning Balance, Shares at Dec. 31, 2021	594,181,604	594,181,604
Share-based compensation	$ 1,038		1,038		1,038
Conversion of notes to equity	3,122	$ 3,122			3,122
Conversion of notes to equity, shares		6,235,512
Shares issued with exercise of warrants	50	$ 50			50
Shares issued with exercise of warrants, shares		88,659
Shares issued for NECC pursuant to acquisition	17,689	$ 17,689	0	0	17,689	0
Shares issued for NECC pursuant to acquisition, shares		28,571,428
Net loss	(5,894)			(5,899)	(5,899)	5
Ending Balance at Mar. 31, 2022	$ 53,537	$ 294,981	$ 53,235	$ (294,756)	$ 53,460	$ 77
Ending Balance, Shares at Mar. 31, 2022	629,077,203	629,077,203

CONDENSED CONSOLIDATED INTERI_4

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (5,894)	$ (11,084)
Adjustments to reconcile net loss to net cash used by operating activities
Depreciation and amortization	1,795	1,046
Equity based compensation	1,038	2,396
Change in fair value of derivative liability	(1,300)	2,532
Accretion of lease liability	1,513	612
Write-off of deposit	0	80
Write-off of fixed asset from terminated lease	0	799
Accretion of contingent consideration	0	124
Accretion of convertible debenture and interest	279	590
Accrued interest on notes payable	1,973	1,097
Interest accrued - lease receivable	208	0
Deferred taxes	(687)	632
Amortization of loan discount upon conversion of debt to equity	0	2,915
Changes in operating assets and liabilities	(1,293)	1,075
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES	(2,368)	2,814
CASH FLOWS FROM INVESTING ACTIVITIES
Payment for NECC business combinations, net of cash acquired	(24,998)	0
Notes receivable repayments	98	63
Sale of dispensaries and interests in cannabis licenses	0	1,093
Purchases of property and equipment	(1,109)	(7,186)
NET CASH (USED IN) INVESTING ACTIVITIES	(26,009)	(6,030)
CASH FLOWS FROM FINANCING ACTIVITIES
Notes payable received, net of costs	0	411
Proceeds from issuance of construction financing liability	16,000	0
Proceeds from the exercise of warrants	50	1,563
Proceeds from the exercise of stock options	0	871
Repayment of notes payable	(1,616)	(755)
NET CASH PROVIDED BY FINANCING ACTIVITIES	14,434	2,090
NET DECREASE IN CASH	(13,943)	(1,126)
CASH, BEGINNING OF QUARTER	22,581	18,932
CASH, END OF QUARTER	$ 8,638	$ 17,806

Nature of Operations

Nature of Operations	3 Months Ended
Nature of Operations	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	Note 1: NATURE OF OPERATIONS 4Front Ventures Corp. (“4Front” or the “Company”) exists pursuant to the provisions of the British Columbia Corporations Act. On July 31, 2019, 4Front Holdings LLC (“Holdings”) completed a Reverse Takeover Transaction (“RTO”) with Cannex Capital Holdings Inc. (“Cannex”) whereby Holdings acquired Cannex and the shareholders of Holdings became the controlling shareholders of the Company. Following the RTO, the Company’s SVS are listed on the Canadian Securities Exchange (“CSE”) under the ticker “FFNT” and are quoted on the OTC (OTCQX: FFNTF). The Company has two primary operating segments: THC Cannabis and CBD Wellness. With regard to its THC Cannabis segment, as of March 31, 2022, the Company operates six dispensaries in Massachusetts, Illinois, and Michigan, primarily under the “MISSION” brand name. As of March 31, 2022, the Company operates three production facilities in Massachusetts, Illinois and California and produces the majority of products that are sold at its own Massachusetts, Illinois, and California dispensaries. Also, as part of its THC Cannabis segment, the Company leases real estate and sells equipment, supplies and intellectual property to cannabis producers in the state of Washington. While marijuana is legal under the laws of several U.S. states (with varying restrictions), the United States Federal Controlled Substances Act classifies all “marijuana” as a Schedule I drug, whether for medical or recreational use. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. The Company’s CBD Wellness segment is focused upon its ownership and operation of its wholly owned subsidiary, Pure Ratios Holdings, Inc. (“Pure Ratios”), a CBD-focused non-THC On January 28, 2022, the Company entered into an agreement and plan of merger (the “NECC Merger Agreement”) with New England Cannabis Corporation, Inc., a Massachusetts Corporation (“NECC”) and a wholly owned subsidiary of the Company entered into a membership interest purchase agreement (the “Everett Purchase Agreement,” and together with the NECC Merger Agreement, the “NECC Merger Agreements”) with Kenneth Stevens to purchase all of the membership interests of 29 Everett, LLC (“29 Everett”), a Massachusetts limited liability company. See Note 7 for further details on the NECC Merger Agreements and corresponding transactions under such agreements. Management continues to evaluate the impact of the COVID-19 The corporate office address of the Company is 5060 North 40th Street, Suite 120, Phoenix, Arizona, and the Company’s registered office is 550 Burrard Street, Suite 2900, Vancouver, British Columbia.

Basis of Presentation

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 2: BASIS OF PRESENTATION The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K, 10-K, There have been no changes to the Company’s significant accounting policies as described in Note 2 of the Company’s 2021 Annual Report on Form 10-K. Principles of consolidation The accompanying condensed consolidated interim financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. The financial results of NECC are included in the condensed consolidated financial statements beginning on January 28, 2022, the merger closing date. The financial statements of the subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
Significant Accounting Policies	Mar. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	Note 3: SIGNIFICANT ACCOUNTING POLICIES (a) Critical accounting estimates and judgments Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of the Company’s condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. The significant judgments made by management in applying the Company’s accounting policies and the key sources of estimation uncertainty were the same as those described in the latest annual consolidated financial statements. We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations. We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary. (b) Recent Accounting Pronouncements Recently Adopted i. In December 2019, the FASB issued ASU 2019-12, 2019-12 2019-12 ii. In August 2020, the FASB issued ASU 2020-06, 470-20) 815-40)”. 2020-06 2020-06 iii. In May 2021, the FASB issued ASU 2021-04, 815-40)”. 2021-04 2021-04 Accounting Pronouncements Not Yet Adopted i. In October 2021, the FASB issued ASU 2021-08, 2021-08

Inventory

Inventory	3 Months Ended
Inventory	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventory	Note 4: INVENTORY The Company’s inventories include the following as of March 31, 2022 March 31, December 31, Raw Materials - unharvested cannabis $ 4,409 $ 2,164 Raw materials CBD and ingredients 37 36 Work in process - flower and extract 11,325 7,780 Finished goods - cultivation supplies 2,351 1,734 Finished goods - packaged products 7,788 8,373 Total $ 25,910 $ 20,087

Property Plant and Equipment

Property Plant and Equipment	3 Months Ended
Property Plant and Equipment	Mar. 31, 2022
Property Plant and Equipment Income Statement Disclosures [Abstract]
Property, Plant and Equipment	Note 5: PROPERTY, PLANT, AND EQUIPMENT Property, plant and equipment and related depreciation are summarized in the table below: March 31, December 31, Land $ 774 $ — Buildings & improvements 13,509 1,483 Construction in process 218 63 Furniture, equipment & other 16,841 13,425 Leasehold improvements 35,514 35,538 Total $ 66,856 $ 50,509 Less: accumulated depreciation (9,041 ) (7,876 ) Total property, plant, and equipment, net $ 57,815 $ 42,633 On January 28, 2022, in conjunction with a business combination with NECC, the Company acquired property, plant, and equipment totaling $15,238 (Note 7). The Company subsequently sold the property, plant, and equipment to a third-party and leased back the equipment from the third-party. As discussed in Note 9, the Company recognized this fact pattern as a failed sale-leaseback transaction, whereby the Company recognized the fixed assets on the balance sheet of NECC and established a construction finance liability for rental payments made as part of the lease agreement. Approximately $33,000 of property and equipment is secured by LI Lending as collateral on the LI Lending note (Note 9). There were no significant contractual commitments for future capital expenditures as of March 31, 2022 and December 31, 2021. Depreciation of property, plant and equipment is computed using the straight-line method over the asset’s estimated useful life. The Company does not depreciate land, which has an indefinite useful life. Depreciation

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended
Intangible Assets and Goodwill	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Note 6: INTANGIBLE ASSETS AND GOODWILL Intangible Assets Intangible assets are recorded at cost less accumulated amortization and impairment losses. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is recognized on a straight-line basis over their estimated useful lives. The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively. Intangible assets and related amortization are summarized in the table below: Licenses Customer Non-Competition Know-How Total Balance, December 31, 2020 $ 20,146 $ 1,668 $ 43 $ 6,933 $ 28,790 Amortization expense — (580 ) (43 ) (1,921 ) (2,544 ) Balance, December 31, 2021 $ 20,146 $ 1,088 $ — $ 5,012 $ 26,246 NECC merger and 29 Everett acquisition (Note 7) 18,000 — — — 18,000 Amortization expense — (145 ) (485 ) (630 ) Balance, March 31, 2022 $ 38,146 $ 943 $ — $ 4,527 $ 43,616 Goodwill Balance, December 31, 2020 $ 23,155 Balance, December 31, 2021 $ 23,155 NECC merger and 29 Everett acquisition (Note 7) 10,249 Balance, March 31, 2022 $ 33,404 Impairment of Intangible Assets and Goodwill On an annual basis, the Company assesses the Company’s reporting units (“RUs”) for indicators of impairment or when facts or circumstances suggest that it is more likely than not that the carrying amount may exceed fair value. For the purpose of impairment testing, goodwill is allocated to the Company’s RUs to which it relates. Goodwill was not tested for impairment during the three months ended March 31, 2022. Three Months Ended March 31, 2021 On January 28, 2022, the Company entered into the NECC Merger Agreements with NECC and 29 Everett for total consideration of $44,689. As part of the purchase price allocation of the acquisition and merger, the Company recognized $18,000 of acquired licenses and $10,249 of goodwill based on the consideration transferred and fair value of assets acquired. For further details on the acquisition and purchase price allocation, see Note 7. Year Ended December 31, 2021 In 2021, management assessed indicators of impairment and concluded the below for the respective RUs: Retail, Production and Ancillary Cannabis Reporting Units Management did not identify any significant negative triggering events that would suggest it is more likely than not that impairment exists. Therefore, further analysis is not required for these RUs. Pure Ratios RU As of March 31, 2022 and December 31, 2021, the accumulated impairment is $13,400, which is due to goodwill impairment of the entire outstanding balance of goodwill on the Pure Ratios segment for the year ended December 31, 2020. As a result, the segment does not have a balance of goodwill or intangible assets remaining as of December 31, 2021.

Acquisitions And Business Combi

Acquisitions And Business Combinations	3 Months Ended
Acquisitions And Business Combinations	Mar. 31, 2022
Business Combinations [Abstract]
Acquisitions and Business Combinations	Note 7: ACQUISITIONS AND BUSINESS COMBINATIONS On January 28, 2022, the Company entered into the merger agreement (the “NECC Merger”) with NECC, Kenneth V. Stevens (“Mr. Stevens”), who is the sole owner of all of the issued and outstanding capital stock of NECC, and 4Front NECC Acquisition Co., a Massachusetts corporation (the “NECC Merger Sub”). At the effective time of the merger, the Company (i) paid Mr. Stevens cash in the amount of $9,000,000, and (ii) issued Mr. Stevens 28,571,428 Class A Subordinate Voting shares of the Company (the “SVS”). In connection with the consummation of the NECC Merger on January 28, 2022, Mission Partners RE, LLC, a Delaware limited liability company wholly owned by the Company (“Mission Partners RE”), and Mr. Stevens entered into the first amendment to that certain membership interest purchase agreement (the “Everett Purchase Agreement”). Pursuant to the Everett Purchase Agreement, the Company (through Mission Partners RE) completed its acquisition six-month anniversary of January 28, 2022. The Merger and Purchase Agreement were recorded as one transaction (collectively, referred to as the “NECC Acquisitions”), as the entities were commonly owned by the same individual and the purchase of Everett LLC was contingent on the Merger with NECC. The NECC Merger was accounted for as a business combination in accordance with ASC 805. The Company has determined preliminary fair values of the assets acquired and liabilities assumed in the NECC Merger. These values are subject to change as the Company completes its determination of the fair value of assets acquired and liabilities assumed. Upon acquisition of NECC and Everett LLC on January 28, 2022, the Company consolidated the operations of Everett LLC into NECC. The Company entered into the NECC Merger in order to acquire cannabis licenses, as well as property and equipment held by NECC to increase the Company’s presence in Massachusetts and the northeastern United States. As part of the NECC Merger, the Company incurred $596,000 in transaction costs, which were expensed as incurred. The following tables presents the preliminary purchase price allocation for the NECC Merger: Cash consideration $ 25,000 Seller note 2,000 Equity consideration - common stock 17,689 Total Purchase Price $ 44,689 Description Fair value Assets acquired: Cash $ 2 Inventory 2,000 Property , plant, and equipment 15,238 Intangible asset - licenses 18,000 Total assets acquired $ 35,240 Liabilities assumed: Accounts payable 800 Total liabilities assumed $ 800 Estimated fair value of net assets acquired $ 34,440 Estimated Goodwill $ 10,249 Goodwill and Intangible Assets Goodwill is represented by the future potential for the generation of positive cash flows and future relationships associated with the Company’s operations. While NECC had yet to generate revenues as of the date of the Merger, the Company identified that the inputs of the business were in place to begin generating revenue during fiscal year 2022. The Company adjusts provisional goodwill balance when new information is obtained regarding the valuation of acquired assets and liabilities during a one-year measurement period from the date of acquisition in accordance with ASC 805-10. The Company has determined that the goodwill recognized in the above acquisition is not deductible for tax purposes. The intangible assets acquired by the Company consist of cannabis licenses for operations. Utilizing alike licenses as a benchmark, the Company determined that the licenses acquired are indefinite lived assets. Unaudited Pro Forma Results The following unaudited pro forma financial information presents the results of operations of the Company and NECC for the three months ended March 31, 2022 and 2021, as if the acquisition had occurred as of the beginning of the first period presented instead of on January 28, 2022. The pro forma information does not necessarily reflect the results of operations that would have occurred had the entities been a single company during those periods. The unaudited pro forma financial information for the Company and NECC is as follows: For the For the Three Months Ended March 31, 2022 2021 Reported Proforma Reported Proforma Revenues $ 26,048 $ 26,048 $ 22,970 $ 22,970 (Loss) income from operations (1,241 ) (1,241 ) 353 344 Net loss $ (5,894 ) $ (5,609 ) $ (11,084 ) $ (11,093 ) Basic and diluted earning (loss) per share $ (0.01 ) $ (0.02 ) $ (0.02 ) $ (0.02 )

Leases

Leases	3 Months Ended
Leases	Mar. 31, 2022
Leases [Abstract]
Leases	Note 8: LEASES The Company has operating leases for its facilities where the Company conducts its operations. These leases have remaining lease terms ranging from 1.25 year s All real estate leases are recorded on the balance sheet. Equipment and other non-real right-of-use non-lease non-lease The Company determines if an arrangement is a lease at inception. The Company must consider whether the contract conveys the right to control the use of an identified asset. Certain arrangements require significant judgment to determine if an asset is specified in the contract and if the Company directs how and for what purpose the asset is used during the term of the contract. There are no material residual guarantees associated with any of the Company’s leases, and there are no significant restrictions or covenants included in the Company’s lease agreements. Certain leases include variable payments related to common area maintenance and property taxes, which are billed by the landlord, as is customary with these types of charges for office space. The Company’s lease agreements occasionally provide an implicit borrowing rate. When implicit borrowing rates are provided, the Company utilizes these implicit borrowing rates to calculate right-of-use For the three months ended March 31, 2022 and 2021 the Company recorded $4,822 and $4,872 in operating lease expense , (a) The Company as a Lessee The following table summarizes the Company’s operating leases: Classification - Consolidated Balance Sheet March 31, December 31, Assets Operating lease assets Operating Lease Assets $ 99,395 $ 100,519 Liabilities Current Operating Current portion of operating lease liabilities 3,700 3,629 Noncurrent Operating Operating lease liabilities 93,505 93,111 Total lease liabilities $ 97,205 $ 96,740 The components of lease expense are included in cost of goods sold, general and administrative expenses, and selling and marketing expenses, based on the underlying use of the right-of-use asset. Maturities of lease liabilities for third-party operating leases as of March 31, 2022 were as follows: Three months ending March 31, 2022 Operating 2022 $ 11,091 2023 15,433 2024 15,859 2025 16,213 2026 16,594 2027 16,603 2028 and Thereafter 227,684 Total undiscounted cash flows $ 319,477 Less discounting (222,272 ) Total lease payments $ 97,205 The Company has right-of-use (b) The Company as a Lessor: The Company leases a building in Elma, Washington that is subleased by the Company to a third party. This sublease is classified as a finance lease with a long term lease receivable balance of $7,543 and a short term lease receivable balance of $2,627 as of March 31, 2022 compared to a long term lease receivable balance of $6,748 and a short term lease receivable balance of $3,630 as of December 31, 2021. This lease generated $692 of the $2,965 and $791 in real estate income for the three months ended March 31, 2022 and 2021, respectively. The Company owned buildings in Olympia, Washington that were leased to a third party. This lease was classified as a finance lease. On December 17, 2020, the Company sold the Olympia building and other assets as part of a sale and leaseback transaction and this lease was cancelled. The Company applied ASC 842 to a new sublease to the same third party and classified the new sublease as an operating lease. The lease receivable was sold to the purchaser of the assets as part of the sale and leaseback transaction. This lease generated $2,273 of the $2,965 and $2,099 of the $2,890 The following table summarizes changes in the Company’s lease March 31, December 31, Balance, beginning of the year $ 10,378 $ 11,045 Interest 692 2,783 Lease payments received (900 ) (3,450 ) Balance, end of the period $ 10,170 $ 10,378 Less current portion (2,627 ) (3,630 ) Long-term lease receivables $ 7,543 $ 6,748 Future minimum lease payments receivable (principal and interest) on the leases are as follows: Operating 2022 $ 2,730 2023 1,575 2024 — 2025 — Thereafter — Total minimum lease payments 4,305 Effect of discounting (667 ) Present value of minimum lease payments 3,638 Present value of residual value of leased property 6,532 Total lease receivable 10,170 Current portion lease receivable (2,627 ) Long-term lease receivable $ 7,543

Notes Payable and Convertible N

Notes Payable and Convertible Notes	3 Months Ended
Notes Payable and Convertible Notes	Mar. 31, 2022
Debt Disclosure [Abstract]
Notes Payable and Convertible Notes	Note 9: NOTES PAYABLE AND CONVERTIBLE NOTES The Company’s notes payable and convertible notes are as follows: LI Lending, May 2020 May 2020 October 2021 Other Loans Total Balance, December 31, 2020 $ 45,362 $ 2,855 $ 11,867 $ — $ 6,931 $ 67,015 Loans advanced, net — — — 14,376 930 15,306 Loan payments (4,671 ) — — — (1,079 ) (5,750 ) Converted to equity — (5,852 ) (11,867 ) — — (17,719 ) Accrued interest 7,575 2,997 — 265 1,124 11,961 Balance, December 31, 2021 $ 48,266 $ — $ — $ 14,641 $ 7,906 $ 70,813 Loans advanced, net — — — — 2,000 2,000 Loan payments (1,506 ) — — — (110 ) (1,616 ) Converted to equity — — — — (2,784 ) (2,784 ) Accrued interest 1,891 — — 279 82 2,252 Balance, March 31, 2022 $ 48,651 $ — $ — $ 14,920 $ 7,094 $ 70,665 Less current portion — — — — (5,385 ) (5,385 ) Long-term portion $ 48,651 $ — $ — $ 14,920 $ 1,709 $ 65,280 Convertible Notes On May 14, 2020, the Company issued $5,827 in convertible notes to existing investors in the Company. The notes pay interest of 5% per annum and have a maturity date of February 28, 2022. $0.25 per share at any time at the option of the holder. The Company can require mandatory conversion at any time that the Company’s stock price remains above $0.50 for 45 consecutive days. In 2021, the Company enacted the mandatory conversion feature and converted the May 2020 Convertible Note balance to subordinate voting shares. As part of issuing the convertible notes, the investors were given the right to exchange stock in the Company into separate convertible notes (swap notes). In total 29,448,468 shares with a value of $13,661 were exchanged for $13,661 in convertible notes. These notes were effective May 28, 2020, have a maturity date of May 28, 2025, and can be converted into Class A Subordinate Voting Shares of the Company for $0.46 per share at any time at the option of the holder. The notes pay no interest if the Company’s annual revenue is greater than $15,000, and 3% annually otherwise. The Company can require mandatory conversion at any time that the Company’s stock price remains above $0.92 for 45 consecutive days. In 2021, the Company exercised the mandatory conversion feature and converted the May 2020 Convertible Note (Swap) balance to subordinate voting shares. On October 6, 2021, the Company entered into a convertible promissory note purchase agreement for $15,000, less issuance costs of $624, resulting in net proceeds of $14,376. The notes pay interest of 6% per annum and have a maturity date of October 6, 2024. The $1.03 per share at any time at the option of the holder. As of March 31, 2022, no payments have been made for this loan. LI Lending LLC On May 10, 2019, the Company entered into a loan agreement with LI Lending LLC, a related party, for $50,000. LI Lending LLC is related because an officer of the Company is a part-owner of LI Lending LLC. As of March 31, 2022, the Company had drawn $45,000 on the loan in two amounts, an initial $35,000 and a final $10,000, both bearing a 10.25% and 12.25% interest rate, respectively. The outstanding balance as of March 31, 2022 is $49,027, less debt discount of $376, for a net balance of $48,651. See Note 1 3 In April 2020, the loan was amended. In exchange for consent to allow the sale of the Pennsylvania and Maryland assets and the release of related collateral, the Company agreed to make prepayments of principal to LI Lending LLC in the amount of $250 per month for an eight-month period beginning on May 1, 2020. The $2,000 prepayment was applied to the initial $35,000 amount , , In December 2020, the loan was amended to allow for the release of collateral for the sale and leaseback transactions described in Note 8 above, which was entered into with Innovative Industrial Properties, Inc. (“IIPR”). The amendment increased both interest rates by 2.5% on the loan amounts but allowed the payments resulting from the incremental interest to be deferred until January 1, 2022. The Company elected to defer payment, and the additional 2.5% interest is accrued each month and added to the balance of the loan. The Company was required to make interest-only payments monthly of 10.25% on the initial $33,000 and 12.25% on the final $10,000 of the loan until January 1, 2022 when the interest rates of 12.75% for the initial $33,000 and 14.75% for the final $10,000 took effect for the remaining term. The loan matures on May 10, 2024. An exit fee of 20% of the principal balance will be due as principal is repaid. Accrued interest expense of $1,891 includes a loan discount accretion expense of $125 Other Outstanding as of March 31, 2022 Healthy Pharms, NECC, and Arkansas entities as follows: Other Subsidiary Terms March 31, December 31, Healthy Pharms Inc. Unsecured convertible note, due November 18, 2021 at 12% per annum $ — $ 2,784 Healthy Pharms Inc. Unsecured promissory note at $0.50 per share due December 18, 2022 at 10% per annum (1) 3,294 3,213 NECC Promissory note due July 28, 2022 at 10% per annum 2,000 — Arkansas Entities Unsecured Promissory note, monthly interest payments at 14% per annum 1,709 1,709 Equipment Loans Secured by equipment, monthly payments beginning in 2021 at 15% per annum — 49 Other Various 91 151 Total Notes Payable and Convertible Notes $ 7,094 $ 7,906 1 (1) In November 2021 ASC 470 Future minimum payments on the notes payable and convertible debt are as follows: March 31, 2022 $ 6,935 2023 143 2024 65,280 2025 — 2026 — Thereafter — Total minimum payments 72,358 Effect of discounting (1,693 ) Present value of minimum payments 70,665 Less current portion (5,385 ) Long-term portion $ 65,280 Construction Finance Liability On January 28, 2022, a wholly owned subsidiary of the Company acquired property at 29 Everett in conjunction with the NECC Merger (see Note 7 for further details on the transaction). Concurrently, effective January 28, 2022, the Company sold a portion of the property it had acquired in the acquisition for $16,000 , less security deposits withheld of $403, which was the cost to the Company. In connection with the sale of the property at 29 Everett, the Company agreed to lease the location back for cultivation, effective on January 28, 2022. The details of the lease included three purchase options that the Company can exercise, in which the Company has the ability to repurchase the property on either the second, fourth, or sixth anniversary of the lease agreement. As the Company plans to exercise one of the three purchase options available, per guidance prescribed in ASC 842, this transaction was determined to be a finance lease. Under this guidance, lease arrangements where assets are sold and leased back, whereby the agreement is classified as a finance lease, does not meet the definition of a sale because control is never transferred to the buyer-lessor. As a result, the transaction was treated as a failed sale-leaseback financing arrangement. On January 28, 2022, the Company recorded a construction finance liability for the proceeds received from the sale to recognize a liability resulting from the failed sale-leaseback transaction. The initial term of the agreement is 20 years, with two options to extend the term for five years each. The initial monthly rent payment is equal to As of March 31, 2022, the total finance liability associated with this transaction is $16,000 .

Share Capital and Equity

Share Capital and Equity	3 Months Ended
Share Capital and Equity	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Share Capital and Equity	Note 10: SHARE CAPITAL AND EQUITY The Company has authorized an unlimited number of Class A Subordinate Voting Shares (“SVS”) and Class C Multiple Voting Shares (“MVS”), all with no par value. In December 2020, the shareholders of the Company passed a resolution to permit the Company to convert all Class B Subordinate Voting Shares (“PVS”) shares into Class A shares and cancel the Class B PVS equity class, which occurred in 2020. All share classes are included within share capital in the consolidated statements of stockholders’ equity on an as-converted basis. Each share class is entitled to notice of and to attend at any meeting of the shareholders, except a meeting of which only holders of another particular class of shares will have the right to vote. All share classes are entitled to receive dividends, as and when declared by the Company, on an as-converted Voting shares activity for the periods presented is summarized as follows: Class A Subordinate Class C Multiple Total Balance, December 31, 2020 537,575,044 1,276,208 538,851,252 Share capital issuances 55,330,352 — 55,330,352 Balance, December 31, 2021 592,905,396 1,276,208 594,181,604 Share capital issuances 34,895,599 — 34,895,599 Balance, March 31, 2022 627,800,995 1,276,208 629,077,203 Class A Subordinate Voting Shares Holders of Class A Subordinate Voting Shares are entitled to one vote in respect of each SVS. Class C Multiple Voting Shares Holders of Class C Multiple Voting Shares are entitled to 800 votes in respect of each MVS. One MVS can convert to one SVS but are not convertible until the later of the date that (i) the aggregate number of PVS and MVS held by the Initial Holders (being the MVS holders on their initial issuance) are reduced to a number which is less than 50% of the aggregate number of PVS and MVS held by the Initial Holders on the date of completion of the Business Combination with Cannex, and (ii) 3 years following the date of the business combination with Cannex. Series Shares outstanding as of As converted to SVS Class A – 627,800,995 627,800,995 Class C – 1,276,208 1,276,208 629,077,203 629,077,203 On November 23, 2020, the Company closed a brokered private placement and issued 24,644,500 Units at a price of C$0.70 per Unit. Each Unit is comprised of one subordinate voting share of the Company and one-half Because of the Canadian dollar denominated exercise price, these warrants do not qualify to be classified within equity and are therefore classified as derivative liabilities at fair value with changes being reported through the statement of operations. On November 23, 2020, the warrants were valued using the Black Scholes option pricing model at $4,229 using the following assumptions: Share Price: C$0.94; Exercise Price: C$0.90; Expected Life: 2 years; Annualized Volatility: 87.73%; Dividend yield: 0.00%; Discount Rate: 0.16%; C$ Exchange Rate:1.31. On March 31, 2022, the warrants were revalued using the Black Scholes option pricing model, using the following assumptions: Share Price: C$1.00; Expected Life: 0.65 years; Annualized Volatility: 70.96%; Dividend yield: 0%; Discount Rate: 1.06%; C$ Exchange Rate: 1.28. The decrease in the value of the derivative liability of $1,300 is reflected in the statement of operations as a $1,300 gain on the change in fair value of the derivative liability.

Warrants

Warrants	3 Months Ended
Warrants	Mar. 31, 2022
Warrants and Rights Note Disclosure [Abstract]
Warrants	Note 11: WARRANTS As of March 31, 2022, there were share purchase warrants outstanding to purchase up to 26,103,578 SVS shares: Series Number of Weight-average Balance, December 31, 2021 26,192,237 $ 0.75 Issued — — Exercised (88,659 ) 0.56 Balance, March 31, 2022 26,103,578 $ 0.75 As of March 31, 2022, the Company has the following warrants outstanding and exercisable: Warrants Outstanding Exercise Price Expiry Date 10,403,150 C$ 0.90 November 23, 2022 209,426 C$ 0.70 November 23, 2022 12,135,922 0.82 December 17, 2022 2,230,080 0.67 January 29, 2023 625,000 C$ 0.80 October 6, 2024 500,000 C$ 0.80 October 6, 2025 26,103,578

Share-Based Compensation

Share-Based Compensation	3 Months Ended
Share-Based Compensation	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Note 12: SHARE-BASED COMPENSATION The Company adopted two equity incentive plans where the Company may grant Class A stock options. Under the terms of the plans, the maximum number of stock options which may be granted are a total of 10% of the number of shares outstanding assuming conversion of all shares to SVS. The exercise price for stock options issued under the plans will be set by the compensation committee of the board of directors but will not be less than 100% of the fair market value of the Company’s shares on the grant date. Stock options have a maximum term of 10 years from the date of grant. Stock options vest at the discretion of the Board. As of March 31, 2022, the Company had the following options outstanding and exercisable on an as-converted Grant Date Strike Price Outstanding Exercisable Life Remaining July 31, 2019 0.10 6,245,840 6,245,840 2.47 July 31, 2019 1.00 7,783,332 7,783,332 0.70 July 31, 2019 1.00 1,166,667 1,166,667 1.52 July 31, 2019 1.50 508,333 508,333 2.20 July 31, 2019 1.50 800,000 800,000 2.21 August 22, 2019 0.80 5,237,720 4,126,609 2.40 August 22, 2019 1.00 6,150,000 4,894,444 2.40 November 1, 2019 0.80 1,200,000 900,000 2.59 February 3, 2020 0.80 375,000 145,833 2.85 June 8, 2020 0.80 25,000 10,417 3.19 July 31, 2020 0.80 1,200,000 1,141,667 3.34 September 15, 2020 0.86 7,315,860 7,315,860 3.46 October 2, 2020 0.77 3,000,000 3,000,000 3.51 November 24, 2020 0.94 1,675,000 1,675,000 3.65 December 2, 2020 1.11 2,900,000 2,900,000 3.68 December 21, 2020 1.06 1,200,000 500,000 3.73 March 18, 2021 1.63 6,650,000 3,325,000 3.97 April 2, 2021 1.36 200,000 133,333 4.01 April 21, 2021 1.58 175,000 116,667 4.06 June 23, 2021 1.56 450,000 300,000 4.23 November 11, 2021 1.33 25,000 6,250 4.62 January 25, 2022 0.89 1,100,000 99,306 4.82 February 1, 2022 0.84 100,000 8,056 4.84 February 17, 2022 0.85 100,000 5,833 4.89 March 1, 2022 1.09 200,000 8,333 4.92 55,782,752 47,116,780 2.79 Stock option activity is summarized as follows: Number of Weighted Weighted Balance December 31, 2020 50,427,065 0.84 3.72 Granted 7,900,000 1.62 5.00 Exercised (2,737,326 ) 1.04 — Forfeited/ Expired (1,306,987 ) 0.43 — Balance December 31, 2021 54,282,752 0.94 2.97 Granted 1,500,000 0.91 5.00 Exercised — — — Forfeited/ Expired — — — Balance March 31, 2022 55,782,752 0.94 2.79 During the three months ended March 31, 2022 and 2021, the Company recognized share-based compensation of $1,038 and $2,396 , In determining the amount of equity-based compensation during the year, the Company used the Black-Scholes option pricing model to establish fair value of options granted during the year with the following key assumptions: 2022 2021 Risk-Free Interest Rate 2.42 % 0.87 % Expected Life (years) 5.00 5.00 Expected Annualized Volatility 71.30 % 86.20 % Expected Dividend Yield — —

Related Parties

Related Parties	3 Months Ended
Related Parties	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Parties	Note 13: RELATED PARTIES Related party transactions LI Lending LLC Linchpin Investors LLC (“Linchpin”), a subsidiary of the Company, and LI Lending LLC (“LI Lending”) entered into a Construction Loan Agreement dated May 10, 2019, as amended, whereby Linchpin received an up-to $45 million loan from LI Lending of which $48,300 was outstanding as of December 31, 2021. Mr. Gontmakher, the CEO of the Company, and Roman Tkachenko, a director of the Company, each hold a 14.28 % ownership interest in LI Lending. Additionally, Mr. Tkachenko is a managing member of LI Lending. LI Lending has advanced the Company a real estate improvement/development loan of $50,000 under that certain Construction Loan Agreement to be used for the acquisition and development of real estate to be used for cannabis operations. The loan matures in May 2024 of the loan advanced includes the notes payable and accrued interest less debt discount of $376 that was outstanding as of March 31, 2022. Of the $49,027 outstanding at March 31, 2022, $1,891 represents interest accrued through March 31, 2022. See Note 9 for details on the outstanding note payable. Pure Ratios Leonid Gontmakher, Chief Executive Officer of the Company, holds an interest in an entity related to iWolf Management, LLC, an online marketing company serving the online CBD market which provided online marketing services during 2020 and 2019 for the Company’s Pure Ratios division. Pure Ratios paid $313 for the three months ended March 31, 2021 to this vendor for management fees, pass through marketing costs and customer service. Pure Ratios did not make any such payments during the three months ended March 31, 2022.

Contingencies

Contingencies	3 Months Ended
Contingencies	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 14: CONTINGENCIES (a) Cannabis Industry Cannabis is still considered a Schedule 1 substance under the Controlled Substance Act. As such, there is an inherent risk related to the federal government’s position on cannabis; additionally, the risk exists, due to the Company’s business in cannabis, that third party service providers could suspend or withdraw services and as well as the risk that regulatory bodies could impose certain restrictions on the issuer’s ability to operate in the U.S.; however, the Company has deemed it not reasonable to estimate a potential liability related to the possible enforcement of laws against the medical cannabis industry. (b) Contingent consideration payable As part of the acquisition of Om of Medicine, LLC and Cannex’s prior acquisition of Pure Ratios, the Company is subject to contingent consideration payable to the sellers. The fair value of the contingent consideration, which is based on specific revenue levels achieved over a 2-3-year Om of Balance, December 31, 2021 $ 2,393 Balance, March 31, 2022 2,393 Less: current portion — Long-term portion $ 2,393 The contingent consideration payable is measured at fair value based on unobservable inputs and is considered a Level 3 financial instrument. The determination of the fair value of these liabilities is primarily driven by the Company’s expectations of the respective subsidiaries achieving certain milestones. The expected milestones were assigned probabilities and the expected related cash flows were discounted to derive the fair value of the contingent consideration. The remaining balance of contingent consideration as of March 31, 2022 is $2,393 , all of which is a long-term contingent consideration. The contingent consideration payment is due in full in April 2023. OM of Medicine: (c) Legal Matters From time to time, the Company may be involved in certain disputes arising in the ordinary course of business. Such disputes, taken in the aggregate, are not expected to have a material adverse effect on the Company. There are also no proceedings in which any of the Company’s directors, officers, or affiliates is an adverse party or has a material interest adverse to the Company’s interest. On August 5, 2019, Richard Hernandez and Commerce Citizens Against Marijuana Corruption (the “Complainants”) filed a complaint (Superior Court of California Case No. 19ST-CV-27029) In December 2021, the Company settled a dispute with an undisclosed defendant. As part of the settlement, the Company recorded a gain on the settlement of $3,768. On January 26, 2022, Savills, Inc. sued the Company in the U.S. District Court for the Southern District of New York. That lawsuit alleges that the Company has breached an alleged agreement with Savills under which the Company was allegedly required to pay Savills a percentage of savings realized under certain incentive programs offered in some jurisdictions, which Savills would assist the Company in obtaining. Savills claims damages of approximately $19,000 in connection with its claim that it obtained benefits for the Company allegedly valued at over $129,000. The Company denies these allegations, denies the Company has obtained such benefits, disputes Savills’ characterization of the facts, and denies liability. The Company has filed a counterclaim against Savills alleging breach of contract by Savills.

Financial Instruments and Finan

Financial Instruments and Financial Risk Management	3 Months Ended
Financial Instruments and Financial Risk Management	Mar. 31, 2022
Investments, All Other Investments [Abstract]
Financial Instruments and Financial Risk Management	Note 15: FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. The Company follows this authoritative guidance for fair value measurements, which defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles in the United States of America, and expands disclosures about fair value measurements. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and Level 3 Inputs for the asset or liability that are not based on observable market data (unobservable inputs). Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the periods ended March 31, 2022 and December 31, 2021. The fair value of the Company’s cash, accounts receivable, other receivables, accounts payable and accrued expenses approximates carrying value due to their short-term nature. The Company’s notes receivable, lease receivables, contingent consideration payable, derivative liabilities, convertible notes payable, construction finance liability, and notes payable approximate fair value due to the instruments bearing market rates of interest or their short-term nature. As the interest rates utilized to calculate these instruments approximates market value interest rates, the carrying amounts of the instruments approximate fair value, which are primarily based on Level 1 inputs. The fair value of stock options granted were estimated based on a Black-Scholes model during the periods ended March 31, 2022 and December 31, 2021. The estimated fair value of the derivative liabilities, which represent embedded put included in the convertible notes payable, represent Level 3 measurements. The following table details the fair value measurements within the fair value hierarchy of the Company’s financial instruments, which includes the Level 3 liabilities: Fair value at March 31, 2022 Total Level 1 Level 2 Level 3 Liabilities: Derivative liability $ 2,202 $ — $ — $ 2,202 Total liabilities $ 2,202 $ — $ — $ 2,202 Fair value at December 31, 2021 Total Level 1 Level 2 Level 3 Liabilities: Derivative liability $ 3,502 $ — $ — $ 3,502 Total liabilities $ 3,502 $ — $ — $ 3,502 The table below provides a summary of the changes in fair value of the derivative liabilities measured on a recurring basis using significant unobservable inputs (Level 3): For the Three Months Ended March 31, 2022 2021 Derivative liability: Balance, beginning of period $ 3,502 $ 5,807 (Gain) loss on fair value of derivative liability (1,300 ) 2,532 Balance, end of period $ 2,202 $ 8,339 There were no transfers (a) Financial Risk Management The Company is exposed in varying degrees to a variety of financial instruments related risks. The Board mitigates these risks by assessing, monitoring and approving the Company’s risk management processes. (b) Credit Risk Credit risk is the risk of loss associated with a counterparty’s inability to fulfill its payment obligations. The Company’s credit risk is primarily attributable to cash, lease receivables, other receivables, and notes receivable. The Company’s maximum credit risk exposure is equivalent to the carrying value of these instruments. The risk exposure is limited to the carrying amounts at the statement of financial position date. The risk to cash deposits is mitigated by holding these instruments with regulated financial institutions. Lease receivables, notes receivables and other receivables credit risk arises from the possibility that principal and interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationships. The Company maintains cash with federally insured financial institutions. As of December 31, 2021, the Company exceeded federally insured limits by approximately $10,866 . The Company did not exceed any federally insured limits at any of its financial institutions for the three months ended March 31, 2022. The Company has historically not experienced any losses in such accounts. As of March 31, 2022, the Company held approximately $29 in cash in a Canadian account that is denominated in C$. As of March 31, 2022 and December 31, 2021, the maximum credit exposure related to the carrying amounts of accounts receivable, other receivables, notes receivable and lease receivables was , respectively. (c) Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company manages liquidity risk through the management of its capital structure. The Company’s approach to managing liquidity is to raise sufficient capital to settle obligations and liabilities when due. The Company has the following gross contractual obligations as of March 31, 2022, which are expected to be payable in the following respective periods: Less than 1 1 to 3 years 3 to 5 years Greater Total Accounts payable and accrued liabilities $ 12,706 $ 1,200 $ — $ — $ 13,906 Convertible notes, notes payable and accrued interest 5,385 65,280 — — 70,665 Contingent consideration payable — 2,393 — — 2,393 Construction finance liability — 16,000 — — $ 16,000 Total $ 18,091 $ 84,873 $ — $ — $ 102,964 (d) Interest Rate Risk Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. (e) Foreign Exchange Risk The Company is exposed to exchange rate fluctuations between United States and Canadian dollars. The Company’s share price is denominated in Canadian dollars. If the Canadian dollar declines against the United States dollar, the United States dollar amounts available to fund the Company through the exercise of stock options or warrants will be less. The Company also has bank accounts with balances of $29 in Canadian dollars. The value of these bank balances if converted to U.S. dollars will fluctuate. While the Company maintains a head office in Canada where it incurs expenses primarily denominated in Canadian dollars, such expenses are a small portion of overall expenses incurred by the Company. The Company does not have a practice of trading derivatives and does not engage in “natural hedging” for funds held in Canada. (f) Other Price Risk Price risk is the risk of variability in fair value due to movements in equity or market prices. The Company is subject to risk of prices to its products due to competitive or regulatory pressures.

Segment Information

Segment Information	3 Months Ended
Segment Information	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Information	Note 16: SEGMENT INFORMATION Reportable Segments Operating segments are components of the Company that combine similar business activities, with activities grouped to facilitate the evaluation of business units and allocation of resources by the Company’s board of directors and management. As of March 31, 2022, the Company had two reportable segments: • THC Cannabis – Production and cultivation of THC cannabis, manufacturing and distribution of cannabis products to own dispensaries and third-party retail customers, ancillary services supporting wholesale operations, and retail sales direct to end consumers • CBD Wellness – Pure Ratios which encompasses the production and sale of CBD products to third-party customers The results of each segment are regularly reviewed by the Company’s Chief Executive Officer, who is the Company’s chief operating decision maker, to assess the performance of the segment and make decisions regarding the allocation of resources. The Company’s chief operating decision maker uses revenue and net loss as measure of segment performance. There are no intersegment sales or transfers. All revenues are derived from customers domiciled in the United States and all assets are located in the United States. The below table presents revenues by type for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 Net Revenues THC Cannabis $ 25,783 $ 22,148 CBD Wellness 265 822 Corporate — — Total Net Revenues 26,048 22,970 Depreciation and Amortization THC Cannabis 847 756 CBD Wellness — 16 Corporate — 2 Total Depreciation and amortization 847 774 Net (Income) Loss THC Cannabis 256 2,838 CBD Wellness (15 ) 3 Corporate 5,658 8,247 Total Net Loss $ 5,899 $ 11,089 Assets March 31, 2022 December 31, 2021 THC Cannabis $ 286,461 $ 238,933 CBD Wellness 725 805 Corporate 3,503 15,801 Total Assets $ 290,689 $ 255,539 On January 28, 2022, the Company acquired assets and liabilities from NECC and 29 Everett in conjunction with the NECC Merger Agreements. As part of the acquisition, the Company acquired $ 18,000 10,249 Goodwill assigned to the THC Cannabis segment as of March 31, 2022 and December 31, 2021 was $33,404 and $23,155 , respectively. Intangible assets, net assigned to the THC Cannabis segment as of March 31, 2022 and December 31, 2021 were $43,616 and $26,246, respectively. The Company did not have any Goodwill or intangible assets assigned to the CBD Wellness segment as of March 31, 2022 and December 31, 2021.

Supplementary Cash Flow Informa

Supplementary Cash Flow Information	3 Months Ended
Supplementary Cash Flow Information	Mar. 31, 2022
Supplemental Cash Flow Information [Abstract]
Supplementary Cash Flow Information	Note 17: SUPPLEMENTARY CASH FLOW INFORMATION Changes in non-cash March 31, 2022 March 31, 2021 Changes in operating assets and liabilities Accounts receivable and other receivables $ (2,309 ) $ 100 Inventory (3,823 ) (934 ) Prepaid expenses 153 (830 ) Deposits 257 (460 ) Accounts payable and accrued liabilities 778 1,393 Taxes payable 3,651 1,806 $ (1,293 ) $ 1,075 Supplemental disclosure of non-cash March 31, 2022 March 31, 2021 Exchange of convertible debt to equity $ 3,122 $ — Change in right-of-use assets and lease liabilities $ 77 $ — Issuance of equity for NECC pursuant to acquisition $ 17,689 $ — Property, plant, and equipment acquired through NECC acquisition $ 15,238 $ — Issuance of notes payable in through NECC acquisition $ 2,000 $ — Inventory acquired through NECC acquisition $ 2,000 $ — • Cash paid for interest for the three months ended March 31, 2022 and 2021 was $1,569 and $818 , • Cash paid for income taxes for the three months ended March 31, 2022 and 2021 was $1,110 and $224 ,

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 18: INCOME TAXES The following table summarizes the Company’s income tax expense: For the Three Months Ended March 31, 2022 2021 Net loss before income taxes $ (2,456 ) $ (8,431 ) Income tax expense (3,438 ) (2,653 ) The Company has computed its provision for income taxes under the discrete method which treats the year-to-date period pre-tax non-deductible Internal Revenue Code (“IRC”) Section 280E denies, at the U.S. federal level, deductions, and credits attributable to a trade or business trafficking in controlled substances. Because the Company is subject to IRC Section 280E, the Company has computed its U.S. tax based on gross receipts less cost of goods sold. The tax provisions for the three months ended March 31, 2022 and 2021, have been prepared based on the assumption that cost of goods sold is a valid expense for income tax purposes. The federal statute of limitation remains open for the tax year to the present. The state income tax returns generally remain open for the tax year through the present. Net operating losses arising prior to these years are also open to examination if and when utilized.

Subsequent Events

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 19: SUBSEQUENT EVENTS On March 30, 2022, the Company entered into an agreement and plan of merger (the “Island Merger Agreement”) by and among the Company, Island Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Island Merger Sub”); Island Global Holdings, Inc., a California corporation (“Island”); and Navy Capital SR LLC, a Delaware limited liability company (“Navy”, and together with the Company, Island Merger Sub, and Island, the “Island Parties”). Pursuant to the terms and conditions of the Merger Agreement, Island Merger Sub will be merged with and into Island, with Island surviving the merger and continuing its corporate existence as a wholly owned subsidiary of the Company (the “Island Merger”). The Island Merger Agreement was effective as of April 13, 2022 (the “Effective Date”). On the Effective Date, the Island Parties consummated the Island Merger, pursuant to the terms and conditions of the Island Merger Agreement, as amended. However, due to administrative and technical issues at the California Office of the Secretary of State, the Island Parties did not receive the certificate of merger evidencing the closing of the Island Merger as of the Effective Date until April 25, 2022. At the Effective Date, pursuant to the terms and conditions of the Island Merger Agreement, as amended, the Company issued to certain shareholders and debtholders of Island an aggregate of: 54 -month, subordinated promissory notes (the “Island Merger Notes”) in the aggregate principal amount of On April 22, 2022, the Parties entered into the first amendment to the Island Merger Agreement to replace the requirement that certain noteholders fund a letter of credit to Island of up to $1,000,000 . In lieu of funding a line of credit, the noteholders agreed to pay the full $1,000,000 The Company is in the process of assessing the fair values of the acquired tangible assets and any intangible assets and liabilities for these acquisitions, and thus, have not presented purchase price allocations as of the date of this filing.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2022
Accounting Policies [Abstract]
Critical accounting estimates and judgments	(a) Critical accounting estimates and judgments Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of the Company’s condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. The significant judgments made by management in applying the Company’s accounting policies and the key sources of estimation uncertainty were the same as those described in the latest annual consolidated financial statements. We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations. We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary.
Recent Accounting Pronouncements	(b) Recent Accounting Pronouncements Recently Adopted i. In December 2019, the FASB issued ASU 2019-12, 2019-12 2019-12 ii. In August 2020, the FASB issued ASU 2020-06, 470-20) 815-40)”. 2020-06 2020-06 iii. In May 2021, the FASB issued ASU 2021-04, 815-40)”. 2021-04 2021-04 Accounting Pronouncements Not Yet Adopted i. In October 2021, the FASB issued ASU 2021-08, 2021-08

Inventory (Tables)

Inventory (Tables)	3 Months Ended
Inventory (Tables)	Mar. 31, 2022
Inventory Disclosure [Abstract]
Summary of Inventory	The Company’s inventories include the following as of March 31, 2022 March 31, December 31, Raw Materials - unharvested cannabis $ 4,409 $ 2,164 Raw materials CBD and ingredients 37 36 Work in process - flower and extract 11,325 7,780 Finished goods - cultivation supplies 2,351 1,734 Finished goods - packaged products 7,788 8,373 Total $ 25,910 $ 20,087

Property Plant and Equipment (T

Property Plant and Equipment (Tables)	3 Months Ended
Property Plant and Equipment (Tables)	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment and Related Depreciation	Property, plant and equipment and related depreciation are summarized in the table below: March 31, December 31, Land $ 774 $ — Buildings & improvements 13,509 1,483 Construction in process 218 63 Furniture, equipment & other 16,841 13,425 Leasehold improvements 35,514 35,538 Total $ 66,856 $ 50,509 Less: accumulated depreciation (9,041 ) (7,876 ) Total property, plant, and equipment, net $ 57,815 $ 42,633

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	3 Months Ended
Intangible Assets and Goodwill (Tables)	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	Licenses Customer Non-Competition Know-How Total Balance, December 31, 2020 $ 20,146 $ 1,668 $ 43 $ 6,933 $ 28,790 Amortization expense — (580 ) (43 ) (1,921 ) (2,544 ) Balance, December 31, 2021 $ 20,146 $ 1,088 $ — $ 5,012 $ 26,246 NECC merger and 29 Everett acquisition (Note 7) 18,000 — — — 18,000 Amortization expense — (145 ) (485 ) (630 ) Balance, March 31, 2022 $ 38,146 $ 943 $ — $ 4,527 $ 43,616
Summary of Goodwill	Balance, December 31, 2020 $ 23,155 Balance, December 31, 2021 $ 23,155 NECC merger and 29 Everett acquisition (Note 7) 10,249 Balance, March 31, 2022 $ 33,404

Acquisitions and Business Com_2

Acquisitions and Business Combinations (Tables) - New England Cannabis Corporation Acquisition [Member]	3 Months Ended
	Mar. 31, 2022
Business Acquisition [Line Items]
Summary Of The Preliminary Purchase Price Allocation Finalized For The NECC Acquisition	The following tables presents the preliminary purchase price allocation for the NECC Merger: Cash consideration $ 25,000 Seller note 2,000 Equity consideration - common stock 17,689 Total Purchase Price $ 44,689 Description Fair value Assets acquired: Cash $ 2 Inventory 2,000 Property , plant, and equipment 15,238 Intangible asset - licenses 18,000 Total assets acquired $ 35,240 Liabilities assumed: Accounts payable 800 Total liabilities assumed $ 800 Estimated fair value of net assets acquired $ 34,440 Estimated Goodwill $ 10,249
Summary Of Pro Forma Information	The unaudited pro forma financial information for the Company and NECC is as follows: For the For the Three Months Ended March 31, 2022 2021 Reported Proforma Reported Proforma Revenues $ 26,048 $ 26,048 $ 22,970 $ 22,970 (Loss) income from operations (1,241 ) (1,241 ) 353 344 Net loss $ (5,894 ) $ (5,609 ) $ (11,084 ) $ (11,093 ) Basic and diluted earning (loss) per share $ (0.01 ) $ (0.02 ) $ (0.02 ) $ (0.02 )

Leases (Tables)

Leases (Tables)	3 Months Ended
Leases (Tables)	Mar. 31, 2022
Leases [Abstract]
Summary of Company's Operating Leases	The following table summarizes the Company’s operating leases: Classification - Consolidated Balance Sheet March 31, December 31, Assets Operating lease assets Operating Lease Assets $ 99,395 $ 100,519 Liabilities Current Operating Current portion of operating lease liabilities 3,700 3,629 Noncurrent Operating Operating lease liabilities 93,505 93,111 Total lease liabilities $ 97,205 $ 96,740
Summary of Maturities Lease Liabilities For Third-Party Operating Leases	Maturities of lease liabilities for third-party operating leases as of March 31, 2022 were as follows: Three months ending March 31, 2022 Operating 2022 $ 11,091 2023 15,433 2024 15,859 2025 16,213 2026 16,594 2027 16,603 2028 and Thereafter 227,684 Total undiscounted cash flows $ 319,477 Less discounting (222,272 ) Total lease payments $ 97,205
Summary of Changes in Lease Receivables	The following table summarizes changes in the Company’s lease March 31, December 31, Balance, beginning of the year $ 10,378 $ 11,045 Interest 692 2,783 Lease payments received (900 ) (3,450 ) Balance, end of the period $ 10,170 $ 10,378 Less current portion (2,627 ) (3,630 ) Long-term lease receivables $ 7,543 $ 6,748
Summary of Future Minimum Lease Payments (Principal and Interest) on Leases (Lessor)	Future minimum lease payments receivable (principal and interest) on the leases are as follows: Operating 2022 $ 2,730 2023 1,575 2024 — 2025 — Thereafter — Total minimum lease payments 4,305 Effect of discounting (667 ) Present value of minimum lease payments 3,638 Present value of residual value of leased property 6,532 Total lease receivable 10,170 Current portion lease receivable (2,627 ) Long-term lease receivable $ 7,543

Notes Payable and Convertible_2

Notes Payable and Convertible Notes (Tables)	3 Months Ended
Notes Payable and Convertible Notes (Tables)	Mar. 31, 2022
Debt Disclosure [Abstract]
Summary of Notes Payable and Convertible Notes	The Company’s notes payable and convertible notes are as follows: LI Lending, May 2020 May 2020 October 2021 Other Loans Total Balance, December 31, 2020 $ 45,362 $ 2,855 $ 11,867 $ — $ 6,931 $ 67,015 Loans advanced, net — — — 14,376 930 15,306 Loan payments (4,671 ) — — — (1,079 ) (5,750 ) Converted to equity — (5,852 ) (11,867 ) — — (17,719 ) Accrued interest 7,575 2,997 — 265 1,124 11,961 Balance, December 31, 2021 $ 48,266 $ — $ — $ 14,641 $ 7,906 $ 70,813 Loans advanced, net — — — — 2,000 2,000 Loan payments (1,506 ) — — — (110 ) (1,616 ) Converted to equity — — — — (2,784 ) (2,784 ) Accrued interest 1,891 — — 279 82 2,252 Balance, March 31, 2022 $ 48,651 $ — $ — $ 14,920 $ 7,094 $ 70,665 Less current portion — — — — (5,385 ) (5,385 ) Long-term portion $ 48,651 $ — $ — $ 14,920 $ 1,709 $ 65,280
Summary of Convertible Debt	Outstanding as of March 31, 2022 Healthy Pharms, NECC, and Arkansas entities as follows: Subsidiary Terms March 31, December 31, Healthy Pharms Inc. Unsecured convertible note, due November 18, 2021 at 12% per annum $ — $ 2,784 Healthy Pharms Inc. Unsecured promissory note at $0.50 per share due December 18, 2022 at 10% per annum (1) 3,294 3,213 NECC Promissory note due July 28, 2022 at 10% per annum 2,000 — Arkansas Entities Unsecured Promissory note, monthly interest payments at 14% per annum 1,709 1,709 Equipment Loans Secured by equipment, monthly payments beginning in 2021 at 15% per annum — 49 Other Various 91 151 Total Notes Payable and Convertible Notes $ 7,094 $ 7,906
Summary of Future Minimum Payments of Notes and Convertible Notes	Future minimum payments on the notes payable and convertible debt are as follows: March 31, 2022 $ 6,935 2023 143 2024 65,280 2025 — 2026 — Thereafter — Total minimum payments 72,358 Effect of discounting (1,693 ) Present value of minimum payments 70,665 Less current portion (5,385 ) Long-term portion $ 65,280

Share Capital and Equity (Table

Share Capital and Equity (Tables)	3 Months Ended
Share Capital and Equity (Tables)	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Summary of Share Capital and Equity	Series Shares outstanding as of As converted to SVS Class A – 627,800,995 627,800,995 Class C – 1,276,208 1,276,208 629,077,203 629,077,203
Summary of Voting Shares Activity	Voting shares activity for the periods presented is summarized as follows: Class A Subordinate Class C Multiple Total Balance, December 31, 2020 537,575,044 1,276,208 538,851,252 Share capital issuances 55,330,352 — 55,330,352 Balance, December 31, 2021 592,905,396 1,276,208 594,181,604 Share capital issuances 34,895,599 — 34,895,599 Balance, March 31, 2022 627,800,995 1,276,208 629,077,203

Warrants (Tables)

Warrants (Tables)	3 Months Ended
Warrants (Tables)	Mar. 31, 2022
Warrants and Rights Note Disclosure [Abstract]
Summary of Warrants Outstanding to Purchase Shares	As of March 31, 2022, there were share purchase warrants outstanding to purchase up to 26,103,578 SVS shares: Series Number of Weight-average Balance, December 31, 2021 26,192,237 $ 0.75 Issued — — Exercised (88,659 ) 0.56 Balance, March 31, 2022 26,103,578 $ 0.75
Summary of Warrants Outstanding And Exercisable	As of March 31, 2022, the Company has the following warrants outstanding and exercisable: Warrants Outstanding Exercise Price Expiry Date 10,403,150 C$ 0.90 November 23, 2022 209,426 C$ 0.70 November 23, 2022 12,135,922 0.82 December 17, 2022 2,230,080 0.67 January 29, 2023 625,000 C$ 0.80 October 6, 2024 500,000 C$ 0.80 October 6, 2025 26,103,578

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
Share-Based Compensation (Tables)	Mar. 31, 2022
Summary of Options Outstanding and Exercisable on an As-Converted Basis	As of March 31, 2022, the Company had the following options outstanding and exercisable on an as-converted Grant Date Strike Price Outstanding Exercisable Life Remaining July 31, 2019 0.10 6,245,840 6,245,840 2.47 July 31, 2019 1.00 7,783,332 7,783,332 0.70 July 31, 2019 1.00 1,166,667 1,166,667 1.52 July 31, 2019 1.50 508,333 508,333 2.20 July 31, 2019 1.50 800,000 800,000 2.21 August 22, 2019 0.80 5,237,720 4,126,609 2.40 August 22, 2019 1.00 6,150,000 4,894,444 2.40 November 1, 2019 0.80 1,200,000 900,000 2.59 February 3, 2020 0.80 375,000 145,833 2.85 June 8, 2020 0.80 25,000 10,417 3.19 July 31, 2020 0.80 1,200,000 1,141,667 3.34 September 15, 2020 0.86 7,315,860 7,315,860 3.46 October 2, 2020 0.77 3,000,000 3,000,000 3.51 November 24, 2020 0.94 1,675,000 1,675,000 3.65 December 2, 2020 1.11 2,900,000 2,900,000 3.68 December 21, 2020 1.06 1,200,000 500,000 3.73 March 18, 2021 1.63 6,650,000 3,325,000 3.97 April 2, 2021 1.36 200,000 133,333 4.01 April 21, 2021 1.58 175,000 116,667 4.06 June 23, 2021 1.56 450,000 300,000 4.23 November 11, 2021 1.33 25,000 6,250 4.62 January 25, 2022 0.89 1,100,000 99,306 4.82 February 1, 2022 0.84 100,000 8,056 4.84 February 17, 2022 0.85 100,000 5,833 4.89 March 1, 2022 1.09 200,000 8,333 4.92 55,782,752 47,116,780 2.79
Summary of Stock Option Activity	Stock option activity is summarized as follows: Number of Weighted Weighted Balance December 31, 2020 50,427,065 0.84 3.72 Granted 7,900,000 1.62 5.00 Exercised (2,737,326 ) 1.04 — Forfeited/ Expired (1,306,987 ) 0.43 — Balance December 31, 2021 54,282,752 0.94 2.97 Granted 1,500,000 0.91 5.00 Exercised — — — Forfeited/ Expired — — — Balance March 31, 2022 55,782,752 0.94 2.79
4Front Holdings LLC
Summary of Stock Options Values using Black-Scholes Model with Key Assumptions	In determining the amount of equity-based compensation during the year, the Company used the Black-Scholes option pricing model to establish fair value of options granted during the year with the following key assumptions: 2022 2021 Risk-Free Interest Rate 2.42 % 0.87 % Expected Life (years) 5.00 5.00 Expected Annualized Volatility 71.30 % 86.20 % Expected Dividend Yield — —

Contingencies (Tables)

Contingencies (Tables)	3 Months Ended
Contingencies (Tables)	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Fair Value of Contingent Consideration	The fair value of the contingent consideration, which is based on specific revenue levels achieved over a 2-3-year Om of Balance, December 31, 2021 $ 2,393 Balance, March 31, 2022 2,393 Less: current portion — Long-term portion $ 2,393

Financial Instruments and Fin_2

Financial Instruments and Financial Risk Management (Tables)	3 Months Ended
	Mar. 31, 2022
Investments, All Other Investments [Abstract]
Schedule of Gross Contractual Obligations	The Company has the following gross contractual obligations as of March 31, 2022, which are expected to be payable in the following respective periods: Less than 1 1 to 3 years 3 to 5 years Greater Total Accounts payable and accrued liabilities $ 12,706 $ 1,200 $ — $ — $ 13,906 Convertible notes, notes payable and accrued interest 5,385 65,280 — — 70,665 Contingent consideration payable — 2,393 — — 2,393 Construction finance liability — 16,000 — — $ 16,000 Total $ 18,091 $ 84,873 $ — $ — $ 102,964
Schedule of Fair Value Measurements With in the Fair Value Hierarchy of The Financial Instruments	The following table details the fair value measurements within the fair value hierarchy of the Company’s financial instruments, which includes the Level 3 liabilities: Fair value at March 31, 2022 Total Level 1 Level 2 Level 3 Liabilities: Derivative liability $ 2,202 $ — $ — $ 2,202 Total liabilities $ 2,202 $ — $ — $ 2,202 Fair value at December 31, 2021 Total Level 1 Level 2 Level 3 Liabilities: Derivative liability $ 3,502 $ — $ — $ 3,502 Total liabilities $ 3,502 $ — $ — $ 3,502
Summary of Changes in Fair Value of the Derivative Liabilities Measured on a Recurring Basis	The table below provides a summary of the changes in fair value of the derivative liabilities measured on a recurring basis using significant unobservable inputs (Level 3): For the Three Months Ended March 31, 2022 2021 Derivative liability: Balance, beginning of period $ 3,502 $ 5,807 (Gain) loss on fair value of derivative liability (1,300 ) 2,532 Balance, end of period $ 2,202 $ 8,339

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
Segment Information (Tables)	Mar. 31, 2022
Segment Reporting [Abstract]
Summary of Revenue By Type	The below table presents revenues by type for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 Net Revenues THC Cannabis $ 25,783 $ 22,148 CBD Wellness 265 822 Corporate — — Total Net Revenues 26,048 22,970 Depreciation and Amortization THC Cannabis 847 756 CBD Wellness — 16 Corporate — 2 Total Depreciation and amortization 847 774 Net (Income) Loss THC Cannabis 256 2,838 CBD Wellness (15 ) 3 Corporate 5,658 8,247 Total Net Loss $ 5,899 $ 11,089 Assets March 31, 2022 December 31, 2021 THC Cannabis $ 286,461 $ 238,933 CBD Wellness 725 805 Corporate 3,503 15,801 Total Assets $ 290,689 $ 255,539

Supplementary Cash Flow Infor_2

Supplementary Cash Flow Information (Tables)	3 Months Ended
Supplementary Cash Flow Information (Tables)	Mar. 31, 2022
Supplemental Cash Flow Information [Abstract]
Summary of Changes in Non-Cash Working Capital	Changes in non-cash March 31, 2022 March 31, 2021 Changes in operating assets and liabilities Accounts receivable and other receivables $ (2,309 ) $ 100 Inventory (3,823 ) (934 ) Prepaid expenses 153 (830 ) Deposits 257 (460 ) Accounts payable and accrued liabilities 778 1,393 Taxes payable 3,651 1,806 $ (1,293 ) $ 1,075
Summary of of non-cash investing and financing activities	Supplemental disclosure of non-cash March 31, 2022 March 31, 2021 Exchange of convertible debt to equity $ 3,122 $ — Change in right-of-use assets and lease liabilities $ 77 $ — Issuance of equity for NECC pursuant to acquisition $ 17,689 $ — Property, plant, and equipment acquired through NECC acquisition $ 15,238 $ — Issuance of notes payable in through NECC acquisition $ 2,000 $ — Inventory acquired through NECC acquisition $ 2,000 $ —

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
Income Taxes (Tables)	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Summary of Income Tax Expense and Effective Tax Rates	The following table summarizes the Company’s income tax expense: For the Three Months Ended March 31, 2022 2021 Net loss before income taxes $ (2,456 ) $ (8,431 ) Income tax expense (3,438 ) (2,653 )

Nature of Operations - Addition

Nature of Operations - Additional Information (Details)	3 Months Ended
Nature of Operations - Additional Information (Details)	Mar. 31, 2022
Nature Of Operations [Line Items]
Number of operating segments	2
Number of dispensaries	6
Massachusetts
Nature Of Operations [Line Items]
Number of production facilities	3
Illinois
Nature Of Operations [Line Items]
Number of production facilities	3

Inventory - Summary of Inventor

Inventory - Summary of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory [Line Items]
Total inventory	$ 25,910	$ 20,087
Unharvested Cannabis
Inventory [Line Items]
Raw materials	4,409	2,164
CBD and Ingredients
Inventory [Line Items]
Raw materials	37	36
Flower and Extract
Inventory [Line Items]
Work in process	11,325	7,780
Cultivation Supplies
Inventory [Line Items]
Finished goods	2,351	1,734
Packaged Products
Inventory [Line Items]
Finished goods	$ 7,788	$ 8,373

Property Plant and Equipment -

Property Plant and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jan. 28, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, pledged as security	$ 33,000
Contractual commitments for future capital expenditures	0			$ 0
Depreciation expense	1,165	$ 463
New England Cannabis Corporation [Member]
Property, Plant and Equipment [Line Items]
Business combination, Recognized identifiable assets acquired, Property, plant, and equipment			$ 15,238
Cost of Sales [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 948	$ 325

Property Plant and Equipment _2

Property Plant and Equipment - Summary of Property and Equipment and Related Depreciation (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 66,856	$ 50,509
Less: accumulated depreciation	(9,041)	(7,876)
Total property and equipment, net	57,815	42,633
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	774	0
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	13,509	1,483
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	218	63
Furniture Equipment And Other [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	16,841	13,425
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 35,514	$ 35,538

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Balance	$ 26,246	$ 28,790
Amortization expense	(630)	(2,544)
NECC merger and 29 Everett acquisition (Note 7)	18,000
Balance	43,616	26,246
Licenses
Finite Lived Intangible Assets [Line Items]
Balance	20,146	20,146
NECC merger and 29 Everett acquisition (Note 7)	18,000
Balance	38,146	20,146
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Balance	1,088	1,668
Amortization expense	(145)	(580)
Balance	943	1,088
Non-competition Agreement
Finite Lived Intangible Assets [Line Items]
Balance	0	43
Amortization expense		(43)
Balance	0	0
Know-how (trade secrets)
Finite Lived Intangible Assets [Line Items]
Balance	5,012	6,933
Amortization expense	(485)	(1,921)
Balance	$ 4,527	$ 5,012

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Summary of Goodwill (Details) - USD ($) $ in Thousands	Jan. 28, 2022	Mar. 31, 2022
Goodwill [Line Items]
Balance		$ 23,155
Balance		33,404
New England Cannabis Corporation And 29 Everett Acquisition [Member]
Goodwill [Line Items]
NECC merger and 29 Everett acquisition (Note 7)	$ 10,249	$ 10,249

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Additional Information (Details) - USD ($) $ in Thousands	Jan. 28, 2022	Mar. 31, 2022	Dec. 31, 2021
Disclosure Of Intangible Assets And Goodwill [Line Items]
Goodwill impairment		$ 0
Accumulated impairment		13,400	$ 13,400
Licenses acquired		18,000
New England Cannabis Corporation And 29 Everett Acquisition [Member]
Disclosure Of Intangible Assets And Goodwill [Line Items]
Goodwill acquired	$ 10,249	$ 10,249
Business combination consideration amount	44,689
Licenses acquired	$ 18,000

Acquisitions and Business Com_3

Acquisitions and Business Combinations - Summary Of The Preliminary Purchase Price Allocation Finalized For The NECC Acquisition (Details) - New England Cannabis Corporation Acquisition [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Business Acquisition [Line Items]
Cash consideration	$ 25,000
Seller note	2,000
Equity consideration - common stock	17,689
Total Purchase Price	44,689
Assets acquired:
Cash	2
Inventory	2,000
Property, plant, and equipment	15,238
Intangible asset - licenses	18,000
Total assets acquired	35,240
Liabilities assumed:
Accounts payable	800
Total liabilities assumed	800
Estimated fair value of net assets acquired	34,440
Estimated Goodwill	$ 10,249

Acquisitions and Business Com_4

Acquisitions and Business Combinations - Summary Of Pro Forma Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Proforma
Revenues	$ 26,048	$ 22,970
(Loss) income from operations	(1,241)	344
Net loss	$ (5,609)	$ (11,093)
Basic and diluted earning (loss) per share	$ (0.02)	$ (0.02)
Reported
Revenues	$ 26,048	$ 22,970
(Loss) income from operations	(1,241)	353
Net loss	$ (5,894)	$ (11,084)
Basic and diluted earning (loss) per share	$ (0.01)	$ (0.02)

Acquisitions And Business Com_5

Acquisitions And Business Combinations - Additional Information (Detail) - New England Cannabis Corporation [Member] - USD ($) $ in Thousands	Jan. 28, 2022	Mar. 31, 2022
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Cash	$ 9,000,000
Business Acquisition, Transaction Costs	$ 596,000
Measurement Period		1 year
Purchase Agreement [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Percentage of voting interests acquired	100.00%
Business Acquistion First Amendment Agreement [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Cash	$ 16,000,000
Business Acquistion First Amendment Agreement [Member] \| Convertible Debt One Issued [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Business combination consideration transferred liabilities incurred	$ 2,000,000
Short term debt fixed interest rate percentage	10.00%
Debt instrument, maturity date	6 months
Subordinate Voting Share [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Number of shares issued as a settlement of consideration	28,571,428

Leases - Summary of Company's O

Leases - Summary of Company's Operating Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets
Operating lease assets	$ 99,395	$ 100,519
Liabilities
Current portion of operating lease liabilities	3,700	3,629
Non-current portion of operating lease liabilities	93,505	93,111
Total lease payments	$ 97,205	$ 96,740

Leases - Summary of Maturities

Leases - Summary of Maturities Lease Liabilities For Third-Party Operating Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
2022	$ 11,091
2023	15,433
2024	15,859
2025	16,213
2026	16,594
2027	16,603
2028 and Thereafter	227,684
Total undiscounted cash flows	319,477
Less discounting	(222,272)
Total lease payments	$ 97,205	$ 96,740

Leases - Summary of Changes in

Leases - Summary of Changes in Lease Receivables (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Balance, beginning of the year	$ 10,378	$ 11,045
Interest	692	2,783
Lease payments received	(900)	(3,450)
Balance, end of the period	10,170	10,378
Less current portion	(2,627)	(3,630)
Long-term lease receivables	$ 7,543	$ 6,748

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Lease Payments (Principal and Interest) on Leases (Lessor) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
2022	$ 2,730
2023	1,575
2024
2025
Thereafter
Total minimum lease payments	4,305
Effect of discounting	(667)
Present value of minimum lease payments	3,638
Present value of residual value of leased property	6,532
Total lease receivable	10,170	$ 10,378	$ 11,045
Current portion of lease receivables	(2,627)	(3,630)
Long-term lease receivable	$ 7,543	$ 6,748

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Leases [Line Items]
Operating lease expense	$ 4,822	$ 4,872
Real estate income	2,965	2,890
Lease incentive receivable, Noncurrent	7,543		$ 6,748
Lease incentive receivable, Current	2,627		$ 3,630
Elma, Building
Leases [Line Items]
Real estate income	692	791
Olympia Building
Leases [Line Items]
Real estate income	$ 2,273	$ 2,099
Minimum
Leases [Line Items]
Lessee incremental borrowing rate percentage	10.25%	10.25%
Lessee, Operating Lease, Remaining lease term	1 month 7 days
Maximum
Leases [Line Items]
Lessee incremental borrowing rate percentage	18.00%	18.00%
Lessee, Operating Lease, Remaining lease term	19 months 13 days

Notes Payable and Convertible_3

Notes Payable and Convertible Notes - Summary of Notes Payable and Convertible Notes (Details) - USD ($) $ in Thousands	Oct. 06, 2021	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Beginning Balance		$ 70,813	$ 67,015
Loans advanced, net		2,000	15,306
Loan payments		(1,616)	(5,750)
Converted to equity		(2,784)	(17,719)
Accrued interest		2,252	11,961
Less current portion		(5,385)
Long-term portion		65,280
Ending Balance		70,665	70,813
LI Lending, LLC
Debt Instrument [Line Items]
Beginning Balance		48,266	45,362
Loans advanced, net			0
Loan payments		(1,506)	(4,671)
Accrued interest		1,891	7,575
Long-term portion		48,651
Ending Balance		48,651	48,266
May 2020 Convertible Notes
Debt Instrument [Line Items]
Beginning Balance		0	2,855
Loan payments		0	0
Converted to equity			(5,852)
Accrued interest		0	2,997
Long-term portion		0
Ending Balance		0	0
May 2020 Convertible Notes (Swap)
Debt Instrument [Line Items]
Beginning Balance		0	11,867
Loans advanced, net			0
Converted to equity		0	(11,867)
Accrued interest		0	0
Long-term portion		0
Ending Balance			0
October 2021 Convertible Note
Debt Instrument [Line Items]
Beginning Balance		14,641
Loans advanced, net	$ 14,376		14,376
Loan payments	$ 0
Converted to equity		0	0
Accrued interest		279	265
Long-term portion		14,920
Ending Balance		14,920	14,641
Other Loans
Debt Instrument [Line Items]
Beginning Balance		7,906	6,931
Loans advanced, net		2,000	930
Loan payments		(110)	(1,079)
Converted to equity		(2,784)
Accrued interest		82	1,124
Less current portion		(5,385)
Long-term portion		1,709
Ending Balance		$ 7,094	$ 7,906

Notes Payable and Convertible_4

Notes Payable and Convertible Notes - Additional Information (Details) $ / shares in Units, $ in Thousands	Jan. 28, 2022USD ($)	Jan. 01, 2022USD ($)	Oct. 06, 2021USD ($)$ / shares	May 28, 2020USD ($)shares$ / shares	May 14, 2020USD ($)shares$ / shares	Apr. 30, 2020USD ($)	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	May 10, 2019USD ($)
Debt Instrument [Line Items]
Issuance of notes payable							$ 2,000	$ 15,306
Other payables							7,094
Repayments of Debt							1,616	5,750
Long term debt, Gross							72,358
Long-term Debt							$ 70,665	70,813	$ 67,015
Acquired property sold	$ 16,000,000
Finance lease term							20 years
Finance Lease Option To Extend							two options to extend the term for five years each.
Lease extend Term							5 years
Initial rent payments							$ 140
Finance Lease Payment Terms And Conditions							3% annual increases over the life of the agreement.
Finance liability							$ 16,000
Security Deposit							403
LI Lending, LLC
Debt Instrument [Line Items]
Issuance of notes payable								0
Maximum borrowing capacity under credit facility											$ 50,000
Amount drawn under credit facility							45,000
Debt instrument, monthly interest-only payments	$ 33,000	$ 33,000				$ 33,000	35,000		33,000	$ 35,000
Debt instrument, final interest-only payments		$ 10,000				10,000	$ 10,000		$ 10,000
Agreed prepayment principal for month						$ 250
Principal amount prepayment period						8 months
Additional Interest rate on final loan amount						12.25%
Debt prepayment						$ 2,000
Increase in interest rate									2.50%
Interest rate on initial loan amount		12.75%				10.25%	10.25%		10.25%
Interest rate on final loan amount		14.75%					12.25%		12.25%
Percentage of exit fee of the principal balance							20.00%
Repayments of Debt							$ 1,506	4,671
Long term debt, Gross							49,027
Debt instrument, Unamortized discount							376
Long-term Debt							48,651	48,266	$ 45,362
Interest payable							1,891
Loan discount accretion expense							125
October 2021 Convertible Note
Debt Instrument [Line Items]
Issuance of notes payable			$ 14,376					14,376
Interest rate, stated percentage			6.00%
Debt instrument, maturity date			Oct. 6, 2024
Debt instrument, convertible, conversion price \| $ / shares			$ 1.03
Debt instrument, Face amount			$ 15,000
Payments of debt issuance costs			624
Repayments of Debt			$ 0
Long-term Debt							$ 14,920	$ 14,641
Convertible Note
Debt Instrument [Line Items]
Issuance of notes payable					$ 5,827
Interest rate, stated percentage					5.00%
Debt instrument, issuance date					May 14, 2020
Debt instrument, maturity date					Feb. 28, 2022
Debt instrument, convertible, conversion price \| $ / shares					$ 0.25
Debt instrument, convertible, stock price trigger \| $ / shares					$ 0.5
Debt instrument, convertible, threshold consecutive trading days \| shares					45
Convertible Notes (Swap)
Debt Instrument [Line Items]
Debt instrument, maturity date				May 28, 2025
Debt instrument, convertible, conversion price \| $ / shares				$ 0.46
Debt instrument, convertible, stock price trigger \| $ / shares				$ 0.92
Debt instrument, convertible, threshold consecutive trading days \| shares				45
Number of shares exchanged in debt \| shares				29,448,468
Issued debt in exchange of convertible equity				$ 13,661
Exchanged shares value				$ 13,661
Debt instrument, interest rate terms				The notes pay no interest if the Company’s annual revenue is greater than $15,000, and 3% annually otherwise
Minimum required annual revenue for interest payment				$ 15,000
Minimum required percentage of annual revenue for interest payment				3.00%

Notes Payable and Convertible_5

Notes Payable and Convertible Notes - Summary of Convertible Debt (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Total Notes Payable and Convertible Notes	$ 7,094	$ 7,906
Healthy Pharms Inc. \| Convertible Note
Debt Instrument [Line Items]
Terms	Unsecured convertible note, due November 18, 2021 at 12% per annum
Total Notes Payable and Convertible Notes	$ 0	2,784
Healthy Pharms Inc. \| Unsecured Debt
Debt Instrument [Line Items]
Terms	Unsecured promissory note at $0.50 per share due December 18, 2022 at 10% per annum (1)
Total Notes Payable and Convertible Notes	$ 3,294	$ 3,213
Arkansas Entities \| Unsecured Debt \| 14% Unsecured Promissory Note
Debt Instrument [Line Items]
Terms		Unsecured Promissory note, monthly interest payments at 14% per annum
Total Notes Payable and Convertible Notes	1,709	$ 1,709
Equipment Loans \| Secured Debt
Debt Instrument [Line Items]
Terms		Secured by equipment, monthly payments beginning in 2021 at 15% per annum
Total Notes Payable and Convertible Notes	0	$ 49
Other
Debt Instrument [Line Items]
Terms		Various
Total Notes Payable and Convertible Notes	$ 91	$ 151
NECC \| Notes Payable, Other Payables
Debt Instrument [Line Items]
Terms	Promissory note due July 28, 2022 at 10% per annum
Total Notes Payable and Convertible Notes	$ 2,000

Notes Payable and Convertible_6

Notes Payable and Convertible Notes - Summary of Convertible Debt (Parenthetical) (Details) - $ / shares	May 14, 2020	Nov. 30, 2021	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt instrument, Maturity date range, End		Dec. 18, 2022
Convertible Note
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price	$ 0.25
Interest rate, stated percentage	5.00%
Debt instrument, maturity date	Feb. 28, 2022
Healthy Pharms Inc. \| Convertible Note
Debt Instrument [Line Items]
Debt instrument, maturity date			Nov. 18, 2021	Nov. 18, 2021
Percentage of paid in kind interest rate			12.00%	12.00%
Healthy Pharms Inc. \| Unsecured Debt
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price			$ 0.5	$ 0.5
Interest rate, stated percentage			10.00%	10.00%
Debt instrument, maturity date			Dec. 18, 2022	Dec. 18, 2022
Arkansas Entities \| Unsecured Debt \| 14% Unsecured Promissory Note
Debt Instrument [Line Items]
Interest rate, stated percentage			14.00%	14.00%
Equipment Loans \| Secured Debt
Debt Instrument [Line Items]
Interest rate, stated percentage			15.00%	15.00%
Debt monthly payment beginning year			2021	2021
New England Cannabis Corporation (NECC) \| Notes Payable, Other Payables
Debt Instrument [Line Items]
Interest rate, stated percentage			10.00%	10.00%
Debt instrument, maturity date			Jul. 28, 2022	Jul. 28, 2022

Notes Payable and Convertible_7

Notes Payable and Convertible Notes - Summary of Future Minimum Payments of Notes and Convertible Notes (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
2021	$ 6,935
2022	143
2023	65,280
2024	0
2025	0
Thereafter	0
Total minimum payments	72,358
Effect of discounting	(1,693)
Present value of minimum payments	70,665	$ 70,813	$ 67,015
Less current portion	(5,385)
Long term portion	$ 65,280

Share Capital and Equity - Addi

Share Capital and Equity - Additional Information (Details) $ / shares in Units, $ in Thousands	Nov. 23, 2020USD ($)shares	Mar. 31, 2022USD ($)$ / shares$ / sharesshares	Mar. 31, 2021USD ($)	Dec. 31, 2021shares	Nov. 23, 2020$ / shares
Class Of Stock [Line Items]
Period when the convertibility of shares from one class to another become exercisable		3 years
Units issued \| shares		34,895,599		55,330,352
Change in fair value of derivative liability \| $		$ 1,300	$ (2,532)
Option Pricing Model
Class Of Stock [Line Items]
Warrants classified as derivative liability value \| $	$ 4,229
Warrants measurement input					0.94
Expected Life	2 years
Option Pricing Model \| Share Price
Class Of Stock [Line Items]
Warrants measurement input		1
Option Pricing Model \| Exercise Price
Class Of Stock [Line Items]
Warrants measurement input					0.9
Option Pricing Model \| Annualized Volatility
Class Of Stock [Line Items]
Warrants measurement input	87.73	70.96
Option Pricing Model \| Dividend Yield
Class Of Stock [Line Items]
Warrants measurement input	0	0
Option Pricing Model \| Measurement Input, Discount Rate
Class Of Stock [Line Items]
Warrants measurement input	0.16	1.06
Option Pricing Model \| Exchange Rate
Class Of Stock [Line Items]
Warrants measurement input		1.28			1.31
Private Placement [Member]
Class Of Stock [Line Items]
Warrants purchase price per share \| (per share)		$ 0.65			$ 0.9
Net proceeds from issuance of stock with warrants \| $	$ 11,557
Payments of share issuance costs \| $	$ 690
Private Placement [Member] \| Share Capital with Unit Price of C$0.70
Class Of Stock [Line Items]
Units issued \| shares	24,644,500
Units issued, price per unit					$ 0.7
Class C Multiple Voting Shares
Class Of Stock [Line Items]
Description of rights attached to each class of capital		800
Percentage of shares of one class held as a percentage of shares of another class		50.00%
Units issued \| shares		0		0

Share Capital and Equity - Summ

Share Capital and Equity - Summary of Voting Shares Activity (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Beginning Balance, Shares	594,181,604	538,851,252
Share capital issuances	34,895,599	55,330,352
Ending Balance, Shares	629,077,203	594,181,604
Class A Subordinate Voting Shares [Member]
Class of Stock [Line Items]
Beginning Balance, Shares	592,905,396	537,575,044
Share capital issuances	34,895,599	55,330,352
Ending Balance, Shares	627,800,995	592,905,396
Class C Multiple Voting Shares [Member]
Class of Stock [Line Items]
Beginning Balance, Shares	1,276,208	1,276,208
Share capital issuances	0	0
Ending Balance, Shares	1,276,208	1,276,208

Share Capital and Equity - Su_2

Share Capital and Equity - Summary of Share Capital and Equity (Details) - shares	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Number of shares outstanding	629,077,203	594,181,604	538,851,252
Class A Shares
Class Of Stock [Line Items]
Number of shares outstanding	627,800,995
Class C Shares
Class Of Stock [Line Items]
Number of shares outstanding	1,276,208
Class A Subordinate Voting Shares
Class Of Stock [Line Items]
Number of shares outstanding	627,800,995	592,905,396	537,575,044
Class C Multiple Voting Shares
Class Of Stock [Line Items]
Number of shares outstanding	1,276,208	1,276,208	1,276,208

Warrants - Summary of Warrants

Warrants - Summary of Warrants Outstanding to Purchase Shares (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Warrants and Rights Note Disclosure [Abstract]
Number of warrants, Beginning balance \| shares	26,192,237
Number of warrants, Issued \| shares
Number of warrants, Exercised \| shares	(88,659)
Number of warrants, Ending balance \| shares	26,103,578
Weighted average exercise price, Beginning balance \| $ / shares	$ 0.75
Weighted average exercise price, Issued \| $ / shares
Weighted average exercise price, Exercised \| $ / shares	0.56
Weighted average exercise price, Ending balance \| $ / shares	$ 0.75

Warrants - Summary of Warrant_2

Warrants - Summary of Warrants Outstanding And Exercisable (Details)	Mar. 31, 2022$ / sharesshares	Mar. 31, 2022$ / sharesshares	Dec. 31, 2021shares
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	26,103,578	26,103,578	26,192,237
Exercise Price CAD 0.90
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	10,403,150	10,403,150
Exercise Price \| $ / shares	$ 0.9
Expiry Date	Nov. 23, 2022	Nov. 23, 2022
Exercise Price CAD 0.70
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	209,426	209,426
Exercise Price \| $ / shares	$ 0.7
Expiry Date	Nov. 23, 2022	Nov. 23, 2022
Exercise Price $0.82
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	12,135,922	12,135,922
Exercise Price \| $ / shares		$ 0.82
Expiry Date	Dec. 17, 2022	Dec. 17, 2022
Exercise Price $0.67
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	2,230,080	2,230,080
Exercise Price \| $ / shares		$ 0.67
Expiry Date	Jan. 29, 2023	Jan. 29, 2023
Exercise Price CAD 0.80
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	625,000	625,000
Exercise Price \| $ / shares	$ 0.8
Expiry Date	Oct. 6, 2024	Oct. 6, 2024
Exercise Price CAD 0.80
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	500,000	500,000
Exercise Price \| $ / shares	$ 0.8
Expiry Date	Oct. 6, 2025	Oct. 6, 2025

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - Equity Incentive Plan - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense	$ 1,038	$ 2,396
Class A Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of stock options available for grant, percentage of number of outstanding shares	10.00%
Minimum exercise price of stock options issued, percentage of fair market value of shares on grant date	100.00%
Maximum term of stock options granted	10 years

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Options Outstanding and Exercisable on an As-Converted Basis (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2022$ / sharesshares	Dec. 31, 2021shares	Dec. 31, 2020shares	Mar. 31, 2022$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding	55,782,752	54,282,752	50,427,065	55,782,752
Exercisable Options	47,116,780			47,116,780
Life Remaining (years)	2 years 9 months 14 days	2 years 11 months 19 days	3 years 8 months 19 days
Stock Options Granted on July 31, 2019, One \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 0.1
Options Outstanding	6,245,840			6,245,840
Exercisable Options	6,245,840			6,245,840
Life Remaining (years)	2 years 5 months 19 days
Stock Options Granted on July 31, 2019, Two \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 1
Options Outstanding	7,783,332			7,783,332
Exercisable Options	7,783,332			7,783,332
Life Remaining (years)	8 months 12 days
Stock Options Granted on July 31, 2019, Three \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 1
Options Outstanding	1,166,667			1,166,667
Exercisable Options	1,166,667			1,166,667
Life Remaining (years)	1 year 6 months 7 days
Stock Options Granted on July 31, 2019, Four \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 1.5
Options Outstanding	508,333			508,333
Exercisable Options	508,333			508,333
Life Remaining (years)	2 years 2 months 12 days
Stock Options Granted on July 31, 2019, Five \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 1.5
Options Outstanding	800,000			800,000
Exercisable Options	800,000			800,000
Life Remaining (years)	2 years 2 months 15 days
Stock Options Granted on August 22, 2019, One \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 0.8
Options Outstanding	5,237,720			5,237,720
Exercisable Options	4,126,609			4,126,609
Life Remaining (years)	2 years 4 months 24 days
Stock Options Granted on August 22, 2019, Two \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 1
Options Outstanding	6,150,000			6,150,000
Exercisable Options	4,894,444			4,894,444
Life Remaining (years)	2 years 4 months 24 days
Stock Options Granted on November 1, 2019 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 0.8
Options Outstanding	1,200,000			1,200,000
Exercisable Options	900,000			900,000
Life Remaining (years)	2 years 7 months 2 days
Stock Options Granted on February 3, 2020 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 0.8
Options Outstanding	375,000			375,000
Exercisable Options	145,833			145,833
Life Remaining (years)	2 years 10 months 6 days
Stock Options Granted on June 8, 2020 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 0.8
Options Outstanding	25,000			25,000
Exercisable Options	10,417			10,417
Life Remaining (years)	3 years 2 months 8 days
Stock Options Granted on July 31, 2020 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 0.8
Options Outstanding	1,200,000			1,200,000
Exercisable Options	1,141,667			1,141,667
Life Remaining (years)	3 years 4 months 2 days
Stock Options Granted on September 15, 2020 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 0.86
Options Outstanding	7,315,860			7,315,860
Exercisable Options	7,315,860			7,315,860
Life Remaining (years)	3 years 5 months 15 days
Stock Options Granted on October 2, 2020 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 0.77
Options Outstanding	3,000,000			3,000,000
Exercisable Options	3,000,000			3,000,000
Life Remaining (years)	3 years 6 months 3 days
Stock Options Granted on November 24, 2020 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 0.94
Options Outstanding	1,675,000			1,675,000
Exercisable Options	1,675,000			1,675,000
Life Remaining (years)	3 years 7 months 24 days
Stock Options Granted on December 2, 2020 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 1.11
Options Outstanding	2,900,000			2,900,000
Exercisable Options	2,900,000			2,900,000
Life Remaining (years)	3 years 8 months 4 days
Stock Options Granted on December 21, 2020 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 1.06
Options Outstanding	1,200,000			1,200,000
Exercisable Options	500,000			500,000
Life Remaining (years)	3 years 8 months 23 days
Stock Options Granted on March 18, 2021 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 1.63
Options Outstanding	6,650,000			6,650,000
Exercisable Options	3,325,000			3,325,000
Life Remaining (years)	3 years 11 months 19 days
Stock Options Granted on April 2, 2021 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 1.36
Options Outstanding	200,000			200,000
Exercisable Options	133,333			133,333
Life Remaining (years)	4 years 3 days
Stock Options Granted on April 21, 2021 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 1.58
Options Outstanding	175,000			175,000
Exercisable Options	116,667			116,667
Life Remaining (years)	4 years 21 days
Stock Options Granted on June 23, 2021 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 1.56
Options Outstanding	450,000			450,000
Exercisable Options	300,000			300,000
Life Remaining (years)	4 years 2 months 23 days
Stock Option Granted on November 11, 2021 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares	$ 1.33
Options Outstanding	25,000			25,000
Exercisable Options	6,250			6,250
Life Remaining (years)	4 years 7 months 13 days
Stock Option Granted on January 25, 2022 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares				$ 0.89
Options Outstanding	1,100,000			1,100,000
Exercisable Options	99,306			99,306
Life Remaining (years)	4 years 9 months 25 days
Stock Options Granted On February 1, 2022 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares				$ 0.84
Options Outstanding	100,000			100,000
Exercisable Options	8,056			8,056
Life Remaining (years)	4 years 10 months 2 days
Stock Options Granted On February 17, 2022 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares				$ 0.85
Options Outstanding	100,000			100,000
Exercisable Options	5,833			5,833
Life Remaining (years)	4 years 10 months 20 days
Stock Options Granted On March 1, 2022 \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike Price \| $ / shares				$ 1.09
Options Outstanding	200,000			200,000
Exercisable Options	8,333			8,333
Life Remaining (years)	4 years 11 months 1 day

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Stock Option Activity (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2022$ / sharesshares	Dec. 31, 2021$ / sharesshares	Dec. 31, 2021$ / sharesshares	Dec. 31, 2020$ / sharesshares
Share-based Payment Arrangement [Abstract]
Number of Options, Beginning Balance \| shares	54,282,752	50,427,065	50,427,065
Number of Options, Granted \| shares	1,500,000	7,900,000	7,900,000
Number of Options, Exercised \| shares		(2,737,326)	(2,737,326)
Number of Options, Forfeited/ Expired \| shares		(1,306,987)	(1,306,987)
Number of Options, Ending Balance \| shares	55,782,752	54,282,752	54,282,752	50,427,065
Weighted Average Price, Beginning Balance \| $ / shares	$ 0.94	$ 0.84
Weighted Average Price, Granted \| $ / shares	0.91	1.62
Weighted Average Price, Exercised \| $ / shares			$ 1.04
Weighted Average Price, Forfeited/ Expired \| $ / shares		0.43
Weighted Average Price, Ending Balance \| $ / shares	$ 0.94	$ 0.94		$ 0.84
Weighted Average Years	2 years 9 months 14 days	2 years 11 months 19 days	2 years 11 months 19 days	3 years 8 months 19 days
Weighted Average Years, Granted	5 years	5 years	5 years

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Stock Options Values using Black-Scholes Model with Key Assumptions (Details) - Equity Based Compensation Options - 4Front Holdings LLC	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-Free Interest Rate	2.42%	0.87%
Expected Life (years)	5 years	5 years
Expected Annualized Volatility	71.30%	86.20%
Expected Dividend Yield	0.00%	0.00%

Related Parties - Additional In

Related Parties - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	May 10, 2019
Related Party Transaction [Line Items]
Long term debt, Gross	$ 72,358
Pure Ratios \| Online CBD Market
Related Party Transaction [Line Items]
Revenue from services to related party	$ 313
LI Lending, LLC
Related Party Transaction [Line Items]
Percentage of ownership interest held	14.28%
Long-term Line of Credit	$ 50,000	$ 48,300	$ 45,000
Debt instrument, Unamortized discount	376
Long term debt, Gross	49,027
Debt instrument interest accrued	1,891
Outstanding debt amount	$ 49,027
Interest Rate	10.25%
Line of Credit Facility, exit fee	$ 9,000
LI Lending, LLC \| Maha Consulting LLC
Related Party Transaction [Line Items]
Long-term Line of Credit	$ 54,000

Contingencies - Summary of Fair

Contingencies - Summary of Fair Value of Contingent Consideration (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Loss Contingencies [Line Items]
Long-term portion	$ 2,393	$ 2,393
Om of Medicine
Loss Contingencies [Line Items]
Balance	2,393	$ 2,393
Long-term portion	$ 2,393

Contingencies - Additional Info

Contingencies - Additional Information (Details) - USD ($)	Jan. 26, 2022	Dec. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Loss Contingencies [Line Items]
Revenues			$ 26,048,000	$ 22,970,000
Gain loss related to litigation settlement		$ 3,768,000
Long term Contingent consideration		$ 2,393,000	2,393,000		$ 2,393,000
Loss contingency damages sought value	$ 19,000,000
Loss Contingency Benefit Value	$ 129,000,000
Om of Medicine
Loss Contingencies [Line Items]
Long term Contingent consideration			2,393,000
Om of Medicine \| Revenue Milestone One \| Minimum
Loss Contingencies [Line Items]
Revenues					$ 3,400,000
Om of Medicine \| Revenue Milestone Two \| Minimum
Loss Contingencies [Line Items]
Revenues			3,500,000
Om of Medicine \| Revenue Milestone Two \| Maximum
Loss Contingencies [Line Items]
Business combination contingent consideration payable			$ 6,900,000

Financial instruments and fin_3

Financial instruments and financial risk management - Schedule of Fair Value Measurements With in the Fair Value Hierarchy of The Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Liabilities:
Derivative liability	$ 2,202	$ 3,502
Total liabilities	2,202	3,502
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Derivative liability	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Derivative liability	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Derivative liability	2,202	3,502
Total liabilities	$ 2,202	$ 3,502

Financial Instruments and Fin_4

Financial Instruments and Financial Risk Management - Summary of Changes in Fair Value of the Derivative Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Derivative Liability [Abstract]
Balance, beginning of period	$ 3,502	$ 5,807
(Gain) loss on fair value of derivative liability	(1,300)	2,532
Balance, end of period	$ 2,202	$ 8,339

Financial Instruments and Fin_5

Financial Instruments and Financial Risk Management - Additional information (Details) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Mar. 31, 2022CAD ($)
Investments, All Other Investments [Abstract]
Fair value, assets, level 1 to level 2 transfers, amount	$ 0	$ 0
Fair value, assets, level 2 to level 1 transfers, amount	0	0
Fair value, liabilities, level 1 to level 2 transfers, amount	0	0
Fair value, liabilities, level 2 to level 1 transfers, amount	0	0
Fair value, equity, level 1 to level 2 transfers, amount	0	0
Fair value, equity, level to level 1 transfers, amount	0	0
Fair value, transfers into (out of) level 3	0	0
Federally insured limits exceeded amount		$ 10,866,000
Cash held with bank accounts	29,000
Maximum credit exposure	$ 14,725,000		$ 12,722,000
Due from banks				$ 29

Financial instruments and fin_6

Financial instruments and financial risk management - Schedule of Gross Contractual Obligations (Details) $ in Thousands	Mar. 31, 2022USD ($)
Financial Instruments [Line Items]
Less than 1 year	$ 18,091
1 to 3 years	84,873
3 to 5 years
Total	102,964
Accounts Payable and Accrued Liabilities [Member]
Financial Instruments [Line Items]
Less than 1 year	12,706
1 to 3 years	1,200
3 to 5 years
Total	13,906
Convertible Notes Notes Payable And Accrued Interest [Member]
Financial Instruments [Line Items]
Less than 1 year	5,385
1 to 3 years	65,280
Total	70,665
Contingent Consideration Payable [Member]
Financial Instruments [Line Items]
1 to 3 years	2,393
3 to 5 years
Total	2,393
Construction finance liability [Member]
Financial Instruments [Line Items]
Less than 1 year	0
1 to 3 years	16,000
Total	$ 16,000

Segment Information - Summary o

Segment Information - Summary of Revenues By Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Total Net Revenues	$ 26,048	$ 22,970
Total Depreciation and Amortization	847	774
Total Net Loss	5,899	11,089
Total Assets	290,689		$ 255,539
THC Cannabis
Segment Reporting Information [Line Items]
Total Net Revenues	25,783	22,148
Total Depreciation and Amortization	847	756
Total Net Loss	256	2,838
Total Assets	286,461		238,933
CBD Wellness
Segment Reporting Information [Line Items]
Total Net Revenues	265	822
Total Depreciation and Amortization	0	16
Total Net Loss	(15)	3
Total Assets	725		805
Corporate
Segment Reporting Information [Line Items]
Total Net Revenues
Total Depreciation and Amortization
Total Net Loss	5,658	$ 8,247
Total Assets	$ 3,503		$ 15,801

Segment Information - Additiona

Segment Information - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)Segment	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Segment Information [Line Items]
Number of reportable segments \| Segment	2
Goodwill	$ 33,404	$ 23,155	$ 23,155
Intangible assets, net	43,616	26,246
THC Cannabis
Segment Information [Line Items]
Goodwill	33,404	23,155
Intangible assets, net	43,616	26,246
CBD Wellness
Segment Information [Line Items]
Goodwill	0	0
Intangible assets, net	$ 0	$ 0

Supplementary Cash Flow Infor_3

Supplementary Cash Flow Information - Summary of Changes in Non-Cash Working Capital (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Changes in operating assets and liabilities
Accounts receivable and other receivables	$ (2,309)	$ 100
Inventory	(3,823)	(934)
Prepaid expenses	153	(830)
Deposits	257	(460)
Accounts payable and accrued liabilities	778	1,393
Taxes payable	3,651	1,806
Equity attributable to 4Front Ventures Corp.	$ (1,293)	$ 1,075

Supplementary Cash Flow Infor_4

Supplementary Cash Flow Information - Summary of non-cash investing and financing activities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Supplemental Cash Flow Information [Abstract]
Exchange of convertible debt to equity	$ 3,122	$ 0
Change in right-of-use assets and lease liabilities	77	0
Issuance of equity for NECC pursuant to acquisition	17,689	0
Property, plant, and equipment acquired through NECC acquisition	15,238	0
Issuance of notes payable in through NECC acquisition	2,000	0
Inventory acquired through NECC acquisition	$ 2,000	$ 0

Supplementary Cash Flow Infor_5

Supplementary Cash Flow Information - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Supplemental Cash Flow Information [Abstract]
Cash paid for interest	$ 1,569	$ 818
Cash paid for income taxes	$ 1,110	$ 224

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Expense and Effective Tax Rates (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Net loss before income taxes	$ (2,456)	$ (8,431)
Income tax expense	$ (3,438)	$ (2,653)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	3 Months Ended
Income Taxes - Additional Information (Details)	Mar. 31, 2022
Federal Statute of Limitation
Income Taxes [Line Items]
Open tax year	2018
State Income Tax Returns
Income Taxes [Line Items]
Open tax year	2017

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 25, 2022	Jan. 28, 2022
New England Cannabis Corporation (NECC) \| Subordinate Voting Shares
Subsequent Event [Line Items]
Business acquisition, number of shares issued \| shares		28,571,428
New England Cannabis Corporation (NECC) \| Merger Agreement [Member] \| Subordinate Voting Shares
Subsequent Event [Line Items]
Short term debt fixed interest rate percentage	6.00%
Subsequent Event \| Merger Agreement [Member] \| Letter of Credit [Member]
Subsequent Event [Line Items]
Line of credit	$ 1,000,000
Subsequent Event \| Merger Agreement [Member] \| Subordinate Voting Shares
Subsequent Event [Line Items]
Promissory notes aggregate principal amount	$ 6,500,000
Subsequent Event \| New England Cannabis Corporation (NECC) \| Merger Agreement [Member] \| Subordinate Voting Shares
Subsequent Event [Line Items]
Business acquisition, number of shares issued \| shares	8,783,716
Debt instrument, maturity date	54 months
Warrants to purchase	$ 2,999,975
Warrants purchase price per share	$ 1